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INTRODUCTION 
The ability to relieve pain has been one of the major achievements of modern medicine. However 
in spite of advances in this science the cornerstone of pain control still remains opioids and non-
steroidal anti-inflammatory drugs (NSAIDs). Opioids were one of the oldest and most efficacious 
ways for man to alleviate the sufferings of pain and remain so even today. Issues of dependence 
and toxicity have marred the reputation of opioids and have defined strict protocols for their 
access and use by trained health professionals in specific clinical scenarios. The history of 
NSAIDs begins with the therapeutic use of willow bark to cure fever, aches and pains and date 
back to the time of Hippocrates (460 B.C.- 377 B.C.), only to be later clearly documented by Rev. 
Edmund Stone in 1763. Similar actions were seen with potions from meadowsweet (Spiraea 
ulmaria).  Kolbe synthesized salicylic acid in 1853, and by 1874 it was being produced 
industrially. In an attempt to modify the toxicity profile of salicylic acid, Felix Hoffmann, a 
chemist with Bayer, in 1899 initiated animal testing of acetylsalicylic acid which later proceeded 
into human testing and marketing as aspirin, the first among the many NSAIDs to come. 
 
NON-STEROIDAL ANTI INFLAMMATORY DRUGS 
Nonsteroidal anti-inflammatory drugs are a group of chemically dissimilar molecules, which have 
similar analgesic, antipyretic and antiinflammatory activities and share similar toxicity profiles.  
NSAIDs exhibit their therapeutic effects by inhibiting the isoforms of cyclooxygenase, resulting 
in a net decrease in prostaglandin synthesis.  
 
These drugs are often clinically classified as traditional NSAIDs (tNSAIDs) or COX-2 selective 
NSAIDs based on their specificity for inhibition of the various isoforms of cyclooxygenase. On 
the basis of chemical structure tNSAIDs are further classified as salicylates (aspirin, diflunisal), 
para-amino phenol derivatives (acetaminophen), acetic acid derivatives (indomethacin, sulinidac 
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and etodolac), fenamates (mefenamic, meclofenamic, and flufenamic acid), hetroaryl acetic acid 
derivatives (tolmetin, ketorolac and diclofenec), propionc acid derivatives (ibuprofen, narpraxon, 
ketoprofen), oxicams (piroxicam, meloxicam), nabumethone and pyrazolon derivatives 
(phenylbutazone, oxyphenbutazone). Attempts to minimize the toxicity of tNSAIDs, which are 
non-selective for COX isoforms, lead to the development of the COX-2 selective inhibitors “the 
coxibs” (Valdecoxib, celecoxib). The optimism of victory over adverse events of tNSAIDs was 
however short lived as studies with COX-2 selective inhibitors demonstrated an increase in 
mortality due to cardiac adverse events. The balance between the suffering of pain and adverse 
effects of treatment with NSAIDs still remains a clinical reality and a challenging field in 
research. 
 
Current clinical status of NSAIDs 
NSAIDs are among the largest group of  drugs sold worldwide. Statistics from the National 
Prescription Audit, 1999-2000, indicate 111,400,000 NSAID prescriptions in United States for 
the year ending in August 2000, which amounted to a net value of approximately $4,800,000,000. 
The sales of over-the-counter analgesics (60% of which were NSAIDs) added an additional 3 
billion dollars to this amount (Laine, 2001). There are reports that suggest prevalence of once-
weekly NSAID use among people in the U.S. Among those who are 65 years old or older, usage 
may be as high as 70% with about half this group taking at least 7 doses per week (Talley et al., 
1995). Data of similar nature is scarce in the Indian scenario, but it is safe to assume that similar 
patterns may exist. The market for NSAIDs in India was estimated to be approximately 
Rs1034.00 crores annually with a growth rate of 6.4% per year. These figures are possibly crude 
indicators of NSAID use in India. Hospital based studies indicate that approximately 65% of 
outpatient prescriptions contain NSAIDs (M. Guptha, 2005). 
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NSAIDs are often ideal drugs in clinical situations as their pain relieving ability is associated with 
a biochemical anti-inflammatory activity. The efficacy to these drugs has been established in 
dental pain (Ong and Seymour, 2003), osteoarthritis (Schnitzer, 2002), rheumatoid arthritis, 
ankylosing spondylitis (Zochling et al., 2006), gout, dysmenorrhea (Connolly, 2003) and 
headache (Lipton et al., 1998).  
 
Other than being used as anti-inflammatory-analgesics, NSAIDs have other indications in 
therapy. Indomethacin, ibuprofen and other NSAIDs have been used to achieve total ductal 
closure in patients with patent ductus arteriosus (PDA) (Thomas et al., 2005). Aspirin and 
ketoprofen along with histamine receptor antagonists have been used to provide relief from 
episodes of vasodilatation and hypotension in patients with systemic mastocytosis (Worobec, 
2000). Indomethacin, in combination with spironolactone and potassium repletion is used to 
improve the biochemical derangements and symptoms associated with Bartter’s syndrome 
(Zawada, 1982). NSAIDs, such as aspirin and sulinidac, and more recently the coxibs have shown 
to have a cancer chemoprotective effect (Muir and Logan, 1999), wherein epidemiological studies 
have demonstrated decreases in the occurrence and progression of colon (Flossmann and 
Rothwell, 2007) and lung cancers (Harris et al., 2007). Aspirin is used, along with large doses of 
the antihyperlipidemic drug niacin, to reduce PGD2 -mediated intense flushing, a major criterion 
limiting the tolerability of niacin (Oberwittler and Baccara-Dinet, 2006). 
 
In recent years, COX-2 specific NSAIDs have made lauded as much-needed alternatives to 
conventional NSAIDs. However, recent reports on increased incidence of cardiovascular events 
among users of COX-2 inhibitors have dampened this enthusiasm. In this scenario, conventional 
NSAIDs continue to be of relevance today as they continue to be a necessity in the treatment of 
chronic arthritis and other related conditions.  
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Adverse effects of NSAIDs 
The promise of pain relief by NSAIDs is often vitiated by toxicity, which most often present as 
gastrointestinal and/or renal complications. Extremes of age, pre-existing morbidities, and co-
administered drugs, often increase the risk of developing adverse effects. 
1. Gastrointestinal toxicity 
 The most common symptoms of toxicity associated with NSAIDs are gastrointestinal, and 
include anorexia, nausea, dyspepsia, abdominal pain and diarrhea. Clinically, they have been 
correlated with increases in the incidence of upper gastrointestinal ulcerations, bleeding, 
perforations and strictures (Abraham and Graham, 2005). NSAID induced gastric and intestinal 
ulcerations were among the first noted complications of this group of drugs (Langman, 1970). 
However it is now realized that in addition to these effects use of NSAIDs is associated with toxic 
effects in the small bowel, colon and rectum with alterations in intestinal function and 
permeability (Thiefin and Beaugerie, 2005).  
 
2. NSAID-induced renal dysfunction 
Approximately 1-5% of patients taking NSAIDs manifest a spectrum of nephrotoxic effects 
(Whelton and Hamilton, 1991). Even though the percentages are small, these figures translate into 
very large numbers considering the incidence and prevalence of NSAID use. NSAIDs are 
considered relatively safe in healthy individuals but the chances of developing renal 
complications increase to almost 20% in patients at high risk (Bush et al., 1991). 
The risk factors for developing acute renal dysfunction following NSAID administration include 
age over 60 years, vascular disease, real or functional volume depletion, preexisting renal 
insufficiency, high renin-angiotensin states and systemic lupus erythematosus (Bush et al., 1991). 
Hyponatremia has been previously described in two groups of patients, infants treated with 
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indomethacin for patent ductus and adults and the elderly who have diseases or are taking drugs 
that impair urinary dilution (Rault, 1993). Elderly age, potassium spring diuretics, preexisting 
renal insufficiency predispose patients to develop hyperkalemia (Zimran et al., 1985, Hay et al., 
2002). Acute interstitial nephritis has been observed at all ages and is difficult to predict (Bush et 
al., 1991). The development of analgesic nephropathy is associated with long term treatment with 
NSAIDs, analgesic abuse and certain drug-analgesic combinations used in treatment (Mackinnon 
et al., 2003). 
 
Clinically, renal adverse effects caused by NSAID toxicity, manifest as follows in a decreasing 
order of frequency: 
1. Fluid and electrolyte imbalance 
a. Sodium chloride and water retention 
b. Only water retention causing severe reversible hyponatremia 
c. Hyperkalemia 
2. Acute deterioration of renal function  (acute renal failure) 
3. Nephritic syndrome with acute interstitial nephritis 
4. Analgesic nephropathy with papillary necrosis 
 
Most of the toxic effects of NSAIDs described, are often attributed to low prostaglandin levels as 
a consequence of COX inhibition (Ejaz et al., 2004). Fluid retention is the most common adverse 
effect of NSAIDs occurring in almost all patients who are exposed (Whelton and Hamilton, 
1991). NSAIDs reduce renal blood flow and glomerular filtration rate (GFR) resulting in sodium 
retention and salt sensitivity (Morgan and Anderson, 2003). Water retention and toxicity as a 
result of NSAID use has been previously described in infants and the elderly (Petersson et al., 
1987). These conditions often manifest clinically as edema (Carder and Weston, 2002), 
hyponatremia (Blum and Aviram, 1980) or increased blood pressure (Morgan and Anderson, 
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2003). However it is often possible to exercise caution and predict the occurrence of these 
complications in patients at risk (Bush et al., 1991). 
 
NSAIDs have been shown to increase serum creatinine levels in patients with compromised renal 
function (Whelton et al., 1990). A similar study by Gurwitz and coworkers demonstrated that 
short-term use of NSAIDs caused reversible azotemia in a sizable proportion of elderly 
individuals (Gurwitz et al., 1990). The risk of developing renal dysfunction in the elderly 
increases with concurrent use of loop diuretics (Gurwitz et al., 1990) or angiotensin converting 
enzyme (ACE) inhibitors (Jolobe, 1999) which are often used to treat co-morbidities like 
hypertension. NSAIDs have been shown to increase the risk of developing acute renal failure 
(ARF) by 58% in the elderly (Griffin et al., 2000). Studies currently predict that the use of 
NSAIDs increases the risk of the first diagnosis of acute renal failure by 3-fold in the general 
population (Huerta et al., 2005). 
 
 Complications involving the renal parenchyma are more difficult to predict and are fortunately 
rare (Bush et al., 1991). Acute tubulointerstitial nephritis is a condition characterized by edema of 
the renal interstitium and interstitial infiltration by eosinophils, mononuclear cells and plasma 
cells (Rossert, 2001). The pathogenesis of tubulointerstitial nephritis is thought to involve direct 
cytotoxicity, inflammation and hypersensitivity (Rastegar and Kashgarian, 1998). NSAID 
induced interstitial nephritis is a reversible condition which may occur with or without nephritic 
syndrome (Ejaz et al., 2004) and has a reported prevalence of 1 in 5000 to 10,000 treated patients 
(Murray and Brater, 1993). Interstitial nephritis has been reported with the use of both tNSAIDs 
and COX-2 selective drugs (Szalat et al., 2004, Brewster and Perazella, 2004).  
 
Classical analgesic nephropathy is associated with habitual consumption of predominantly 
analgesic products and may take several years to develop. The pathological hallmark of this 
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condition is interstitial fibrosis and the insidious development of renal failure (Henrich, 1998). 
Renal papillary necrosis is one of the first features to appear and gradually develops into 
progressive secondary cortical degeneration on further analgesic abuse (Gregg et al., 1989). This 
progresses into end stage renal failure with up to 20% of the patients needing dialysis or renal 
transplantation (Nanra et al., 1978). Chronic analgesic abuse is associated with the development 
of upper urothelial carcinomas as shown by animal studies (Hultengren et al., 1965) and 
observational studies in humans (Handa, 1979). However these results have not been established 
by case control studies (Linet et al., 1995). 
 
INDOMETHACIN 
Indomethacin is a methylated indole derivative, which like other NSAIDs has prominent 
antiinflammatory and analgesic-antipyretic properties. It is believed to exert its analgesic effects 
on both the central nervous system and locally at the site of inflammation. 
 
Indomethacin is known to exert its antiinflammatory activity by inhibiting both isoforms of 
cyclooxygenase (Shen and Winter, 1977) in a concentration dependent manner (Kulmacz and 
Lands, 1985). The process of inhibition of COX is time-dependent and involves an initial 
competitive reversible phase followed by an irreversible phase characterized by a decay of 
enzyme activity, which is not be reversed by dilution (Smith and Lands, 1971). The resultant 
enzyme had a net activity of 4-10% of the original enzyme. It is postulated that the time-
dependent effects are mediated due to conformational changes in the enzyme and do not involve 
any covalent modifications (Kulmacz and Lands, 1985). 
 
As indomethacin is highly lipid soluble, it is well absorbed orally, achieving 80-100% 
bioavailability. Peak plasma concentration is achieved within 1 to 2 hours after a single oral dose. 
The drug is 90% bound to plasma proteins and has an association constant of 0.86×103 M–1 
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(M=molarity). Albumin is the predominant binding protein with an estimated 15 binding sites per 
molecule. Serum levels in patients with long term indomethacin therapy measured after a last 
dose of 25mg was found to range from 1.5-3µg/ml (Hvidberg et al., 1972). Indomethacin crosses 
the blood-brain barrier within 30 minutes of an intramuscular injection and achieves CSF 
concentrations similar to plasma concentrations within 2 hours. However analgesic activity was 
not found to correlate with neither serum nor CSF concentrations (Bannwarth et al., 1990). 
 
The half-life of indomethacin is variable because of enterohepatic circulation but averages around 
2 ½ hours. Studies with 14C labeled indomethacin indicate that 50% of the drug administered by 
intravenous route underwent enterohepatic recirculation. Absorption and/or reabsorption of the 
drug happen to be more rapid and uniform by the rectal route (Kwan et al., 1976). 
 
Indomethacin in its free form and as its glucoronide conjugate is found in early plasma samples 
after oral doses. These free and conjugated forms of indomethacin are excreted in bile, 
hydrolysed in the intestine and reabsorbed by enterohepatic circulation and are responsible for 
variations in half-life. O-demethylation and N-deacylation constitute other major metabolic 
pathways for the conversion of indomethacin into inactive metabolites and may occur 
independently or in a sequential manner (Duggan et al., 1972). Studies with 14C  labeled 
indomethacin to assess O-demethylation demonstrated the formation of O-
desmethylindomethacin, N-deschlorobenzoylindomethacin and O-desmethyl-N-
deschlorobenzoylindomethacin (Harman et al., 1964) as the major metabolites in this pathway. 
The formation of O-desmethylindomethacin is thought to be a major pathway in man as it 
represents 40-55% of the indomethacin excreted in the urine (Duggan et al., 1972). This 
conversion of indomethacin to its demethylated metabolite in humans, occurs in the liver 
microsomes, catalysed by P450 2C9 (Nakajima et al., 1998). The N-deacylation pathway is 
thought to occur independently of CYP P450 system and is catalyzed by a carboxylesterase 
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localized to the microsomes in pig liver (Terashima et al., 1996). This carboxylesterase catalyzed 
hydrolysis of indomethacin has also been noted in human and rabbit liver homogenates but is 
absent in rats and mice (Terashima et al., 1996). 
 
Further metabolism of O-desmethyl N-deschlorobenzoylindomethacin (DMBI) has been noted in 
activated neutrophils by hypochlorous acid and the myeloperoxidase system to give rise to 
reactive iminoquinone intermediates (Ju and Uetrecht, 1998).  
 
About 10-20% of indomethacin is excreted unchanged in urine, partly by tubular secretion. Free 
and conjugated metabolites are excreted through bile, urine and feces. 
 
Indomethacin-induced renal dysfunction 
The renal toxicity of indomethacin is well documented in literature both when used alone and in 
combination with other nephrotoxic agents. Indomethacin is known to cause disturbances in fluid 
and electrolyte balance, hypertension, acute renal failure, acute interstitial nephritis and chronic 
interstitial nephritis with renal papillary necrosis. There are also reports of renal dysgenesis 
(Restaino et al., 1991) and renal dysfunction (Buderus et al., 1993) following exposure to 
indomethacin in utero. 
 
 The most common renal adverse effect is sodium and water retention (Somova et al., 1984) and 
(Baker et al., 2005). Similar evidence has been noted in experimental animals also (Bartha and 
Hably, 1978).  Indomethacin has also been noted to cause hyponatremia in infants and elderly 
patients with renal disease who have a preexisting impairment of urine concentrating mechanisms 
(Rault, 1993). Hyperkalemia in a background hyporeninemic hypoaldosteronism is an adverse 
effect which is more frequently associated with indomethacin than other NSAIDs (Tan et al., 
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1979), (Goldszer et al., 1981) and (MacCarthy and Stokes, 1979). However the pathogenesis of 
hyperkalemia has been a subject of much debate as controlled experiments failed to demonstrate 
these effects conclusively (Padhani et al., 1987, Clive et al., 1992). 
 
• Acute renal failure due to the renal effects of indomethacin occurs in elderly (Gary et al., 
1980) or hypovolumic patients (Weinberg et al., 1985). Acute interstitial nephritis is a reversible 
condition which has been described with the use of several NSAIDs, including indomethacin 
(Green et al., 1985). Long-term use of indomethacin with or without other analgesic agents is 
associated with the development of chronic irreversible interstitial nephritis and renal papillary 
necrosis (Jackson and Lawrence, 1978). 
 
• Other adverse effects: 
• Indomethacin like other NSAIDs has been associated with other toxicities such as 
gastropathy (Filaretova et al., 2002), enteropathy (Zuccato et al., 1992) and hepatotoxicity 
(Kelsey and Scharyj, 1967). Therefore indomethacin serves as the prototype drug to study the 
effects of toxicity of traditional NSAIDs. 
•  
OXIDATIVE STRESS 
Oxidative stress refers to a whole spectrum of changes in tissue or cellular function in response to 
a mismatch in the rate of formation of reactive oxygen species (ROS) or reactive nitrogen species 
and the rate of their removal by antioxidant defense mechanisms. Such changes in the redox 
status of the internal cellular environment play an important physiological role in anti-microbial 
defense and cellular signaling. Oxidative stress plays a central role in variety of pathological 
conditions ranging from inflammatory conditions to cancers. 
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Maintaining a reducing environment within the cell is essential for maintaining structural and 
functional integrity of macromolecules such as proteins, lipids and DNA. Oxidative stress 
chemically may be described as either a large increase in the “cellular reduction potential” 
(i.e.becoming less negative) or a large decrease in the “reducing capacity of cellular redox 
couples” (Schafer and Buettner, 2001). The effect of such a stress depends on its magnitude and 
may range from initiation of antioxidant defense to triggering apoptosis or even necrosis (Nkabyo 
et al., 2002, Schafer and Buettner, 2001, Attene-Ramos et al., 2005).  
 
Endogenous pro-oxidant and antioxidant mechanisms: 
Oxidative stress within cells is a result of an unfavorable tilt in the fine balance between pro-
oxidant species and antioxidant mechanisms. The sources and importance of major players in this 
balance within normal cells is highlighted in the table below: 
Pro-oxidants 
Oxidant Description and mechanism of generation 
O2-  superoxide anion This radical is generated by one electron reduction of molecular 
oxygen. Superoxide radicals may be formed during electron 
transfer in the mitochondria, uncoupling of eNOS or by 
enzymes such as NADPH oxidase, xanthine oxidase and 
cytochrome P-450. Destroys Fe-S centers by oxidation 
(Scandalios, 2005, Fortuno et al., 2005). 
H2O2, hydrogen peroxide This is a non-radical ROS. Hydrogen peroxide in cells is formed 
by dismutation of superoxide, β-oxidation and proton induced 
decomposition of superoxide by monooxygenases and oxidases 
(Scandalios, 2005, Fortuno et al., 2005). 
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•OH hydroxyl radical The hydroxyl radical is formed during the reaction of H2O2 with 
O2-  (Haber-Weiss) or Fe2+ (Fenton). Highly reactive with all 
macromolecules (Scandalios, 2005, Fortuno et al., 2005). 
OONO-, peroxynitrite Strong pro-oxidant molecule formed by the inactivation of NO 
by O2-  (Scandalios, 2005, Fortuno et al., 2005). 
HOCl, hypochlorous acid Hypochlorous acid is a strong oxidizing agent that can attack a 
variety of biomolecules and is generated by activated 
neutrophils. Myeloperoxidase catalyses the oxidation of halides 
by H2O2 to generate hypochlorous acid which exists in 
equilibrium with the hypochlorite ion (Halliwell et al., 1988). 
RO•, alkoxy 
ROO•, peroxy radicals 
These radicals are produced from lipid and protein 
intermediates in the presence of oxygen radicals by radical 
addition to double bonds or hydrogen abstraction. Lipid forms 
participate in lipid peroxidation reactions (Hawkins and Davies, 
2001, Blair, 2001) 
 
 
Enzymes with primary antioxidant role 
Enzyme Subcellular location and reaction catalysed  
Superoxide dismutase Cytosol (Cu/ZnSOD); mitochondrion (MnSOD) 
2•O2-   + 2 H+ H2O2 + O2 
Catalase Peroxisome; cytosol; mitochondria 
2 H2O2  O2 + 2 H2O 
Glutathione reductase Mitochondrion; cytosol 
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2 GSH + NADP+  GSSG + NADPH + H+ 
Glutathione-S transferases Cytosol; microsomal 
RX + GSH  HX + R-S-G 
R may be an aliphatic, aromatic or heterocyclic group; X 
may be a sulfate, nitrile or halide group. 
Peroxidases (non-specific) Cytosol; cell membrane bound 
donor + H2O2  oxidized donor + 2 H2O 
Dehydroascorbate reductase Cytosol 
2 GSH + dehydroascorbate  GSSG + ascorbate 
Reference: (Scandalios, 2005)                 
 
Oxidative stress and NSAIDs  - “the paradox” 
Mechanistic studies on the enzyme cyclooxygenase suggest that the conversion of arachidonic 
acid to the prostaglandin precursor PGH2 occurs through a two-step process. The first step 
involves the cyclooxygenase reaction where in arachidonic acid is converted into its cyclic 
endoperoxide PGG2. PGG2 is then converted to PGH2 through a second peroxidase reaction that 
is also catalyzed by the same enzyme. This reaction involves the release of a superoxide radical. 
NSAIDs were believed to exert their anti-inflammatory effects by inhibiting both prostaglandin 
synthesis and superoxide radical generation (Palmer, 1995). 
 
However, studies on NSAID toxicity have shown that NSAIDs cause a paradoxical increase in 
oxidative stress in animals, in both the kidney and gastric mucosa (Basivireddy et al., 2004, 
Basivireddy et al., 2003). The oxidative stress seen in these studies, involve both excessive 
generation of pro-oxidants and impairment in defense responses. The various mechanisms, which 
are thought to play a role in such process, are as follows: 
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Generation of free radicals: 
1. Mitochondrial uncoupling:  
The possibility of mitochondria as a source contributing to the development of oxidative 
stress initially came to light with electron microscopy studies show ballooning and 
vacuolization of mitochondria, features suggestive of uncoupling of oxidative 
phosphorylation within an hour of dosing with indomethacin (Somasundaram et al., 1997). 
 
2. Neutrophil infiltration:  
Neutrophil adhesion to the vascular endothelium has been described as one of the earliest 
events in NSAID mediated gastric injury. Reduction in mucosal injury in neutropinic rats and 
in animals treated with antibodies to β2 integrin CD-18 suggests the pivotal role of this event 
(Wallace et al., 1993). Intravital video microscopy studies to monitor leucocyte-endothelial 
cell adhesion show an increase in neutrophil endothelial adhesion on treatment with asprin or 
indomethacin. Leukotriene B4 receptor antagonists effectively decreased these interactions 
(Kurose et al., 1996). Interactions between leukocyte and endothelial cells are thought to lead 
to gastric microvessels occlusion and ischaemic/hypoxic endothelial-epithelial cell damage 
(Fiorucci et al., 1999). However, even though neutrophil infiltration is a salient feature of 
NSAID induced renal toxicity (Basivireddy et al., 2004), such interactions between 
neutrophils and endothelial cells have not been reported in the kidney. 
 
3. Role of peroxidases: 
 The stomach, intestine and liver are tissues demonstrating high levels of peroxidase activity. 
Furthermore, both the intestine and kidney demonstrate significant neutrophil infiltration with 
high activity of myeloperoxidase in response to administration of NSAIDs (Basivireddy et 
al., 2004, Menozzi et al., 2006). Indomethacin and horseradish peroxidase/H2O2 in the 
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presence of Fe3+ causes peroxidation of lipids from liver microsomes in a time dependent 
manner (Miura et al., 2002). Protection offered by the enzyme superoxide-dismutase against 
both lipid peroxidation and Fe3+ reduction suggests the presence of the superoxide anion 
(Miura et al., 2002). Electron spin resonance studies also indicate the presence of an 
indomethacin free radical in this process (Miura et al., 2002, Chattopadhyay et al., 2006). 
 
4. Metabolism of NSAIDs to reactive radicals:  
The role of free radicals generated from indomethacin or its metabolites in causing an altered 
redox balance in tissues has been previously reported (Miura et al., 2002). Metabolism of O-
desmethyl N-deschlorobenzoylindomethacin (DMBI) has been noted in activated neutrophils 
to give rise to reactive iminoquinone intermediates (Ju and Uetrecht, 1998). These reactive 
intermediates have been quoted to play a major role in idiosyncratic drug reactions such as 
agranulocytosis induced by indomethacin. 
 
Impairment of endogenous antioxidant defense 
The redox status of a cell or tissue is a reflection of the existing balance between pro-oxidants and 
antioxidants. An impaired antioxidant defense mecanisim is often contributory to oxidative stress 
seen. In the case of NSAIDs this may be exemplified by studies on indomethacin induced 
hepatotoxicity in rats, which showed depression in expression levels of antioxidant enzymes 
glutathione reductase, superoxide dismutase and glutathione transferase(LaFramboise et al., 
2006). Administration of aspirin or nimusulide in rats reduces the activity of catalase, superoxide 
dismutase and glutathione-S-transferase in the intestine (Nair et al., 2006). A decrease in 
glutathione reductase and glutathione-s-transferase activity is also noted with ketoprofen (Nieto et 
al., 2002). The comman factors seen among these NSAIDs appears to be a net reduction in the 
levels of reduced glutathione which is a predisposing condition to the devlopment of oxidative 
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stress (Nieto et al., 2002, Nair et al., 2006). Previous studies done in our lab also show similar 
results and are in agreement with the results above. 
 
Oxidative stress and renal dysfunction: 
 Oxidative stress plays an important role in the kidney, not only in mediating pathological 
changes, but also in regulating normal physiological adaptations. The impact of oxidative stress 
in the kidney may arise from an increased generation of ROS, a decrease in the antioxidant 
defense mechanisms or by a combination of both. 
 
Initial interest in ROS as vasoactive mediators focused on superoxide free radical (O2-•) and its 
interaction with nitric oxide (NO) as a mechanism to explain endothelial dysfunction and renal 
vasoconstriction (Laursen et al., 1997). Superoxide radicals generated by NADPH oxidase, under 
the influence of angiotensin II, modify tubulovascular crosstalk in the outer medulla. The effects 
of chronic angiotensin-II infusion include renal cortical hypoxia, hypertension, increased 
NADPH-oxidase activity, reduced expression of endothelial cell superoxide dismutase and 
inefficient usage of O2 for tubular transport (Welch et al., 2005). It is interesting to note that these 
effects of angiotensin II are blunted or prevented by Tempol, a well-validated spin trap for 
superoxide (Welch et al., 2005, Krishna et al., 1996, Konorev et al., 1995).  
 
It is well known that reactive oxygen species  (ROS) are proximal effectors in multiple signaling 
pathways implicated in organ dysfunction or damage (Wu, 2006, Fialkow et al., 2007). 
Downstream effects from ROS involve the activation of pro-inflammatory pathways such as 
nuclear factor kappa B (NFκB), activator protein-1 (AP-1) and peroxisome proliferator-activated 
receptor (PPARs) (Fialkow et al., 2007, Wilcox and Gutterman, 2005). The activation of these 
signaling cascades result in generation of secondary mediators involved in cellular adhesion 
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(mediated by Intracellular adhesion molecule-1 and vascular cell adhesion molecule-1), 
extracellular matrix remodelling (matrix metalloproteinases), inflammation (cyclooxygenase and 
phospholipase A2) and cytokine production (epidermal growth factor). These substances in 
association with their more proximal inducers perpetuate organ damage (Wilcox and Gutterman, 
2005). 
 
The central role of ROS in diffrent renal pathologies stand as a testimony to the mechanism 
described above. Increases in glomerular levels of H2O2 and OH• have been observed after 
treatment with puromycin aminonucleoside in rats, a standard model for human minimal-change 
glomerulopathy (Gwinner et al., 1997, Kawaguchi et al., 1992). Similar evidence of the role of 
oxidative stress has been established in mesangioproliferative GN give expansions, membranous 
GN and segmental necrotizing GN and animal models of these conditions(Gwinner and Grone, 
2000) . Reactive oxygen species have been implicated in several other renal diseases, including 
diabetic nephropathy, hypertensive nephropathy, ischemia reperfusion injury and transplant 
rejection (Singh et al., 2006, Nath and Norby, 2000, Johnson and Weinberg, 1993, Tan et al., 
2007, Ha and Lee, 2005).  
 
ANTIOXIDANTS 
Generation of reactive oxygen species is a ubiquitous phenomenon in all-living organisms. 
However reactive oxygen species can induce peroxidation of cellular lipids, proteins and DNA, 
which is deleterious to the organism. In a bid to reduce the impact of such reactive molecules 
cells have evolved various types of antioxidant and repair mechanisms. 
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Antioxidants may be broadly defined as agents that limit the deleterious effects of free radical-
induced oxidant reactions. Some of the antioxidants that have an important role in health and 
disease are as follows: 
 
Antioxidants utilized by the body 
Endogenous antioxidants  Exogenous/dietary antioxidants 
Enzymes and their substrates: 
Superoxide dismutases (SOD): 
• MnSOD mitochondrial 
• CuZnSOD cytosolic 
Catalase 
Glutathione peroxidase 
Metal ion sequestration: 
Metallothioneins 
Transferrin 
Lactoferrin 
 
 
 
 
 
 
 
 
 
 
Naturally occurring dietary antioxidants 
Vitamin E 
Vitamin C 
β-Carotene 
Flavinoids and plant penolics 
Food additives serving as antioxidants 
Propyl gallate 
Butylated hydroxyanisole 
Butylated hydroxytoluene 
 
 
Antioxidants can be classified based on mechanism of action as:  
1. Preventive antioxidants: These antioxidants reduce the rate of initiation of peroxidation. 
Examples of preventive antioxidants are: 
i. endogenous: catalase, peroxidases and metallothionins 
ii. exogenous: diethylenetriaminepentaacetate (DPTA) and 
ethylenediamine-tetraacetate (EDTA) 
2. Chain breaking antioxidants: These antioxidants stop the propagation of peroxidation 
chain reactions. Examples of chain breaking antioxidants are: 
i. endogenous: superoxide dismutase and urate (aqueous phase) and 
vitamin E (lipid phase). 
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ii. exogenous: polyphenols and aromatic amines 
 
 
 
ZINC 
Zinc is a metal belonging to the class IIb family on the periodic table, with an atomic number of 
30 and an average atomic weight of 65.38amu.   
 
The tissue concentration of zinc is 10 to 30 µg/g rat tissues (Onosaka and Cherian, 1982). The 
levels are very high in the prostate. The zinc in the cells mainly distributes in the cytoplasam and 
is protein-bound (Cousins, 1986). Zinc supplementation results in accumulation in four organs the 
pancreas, liver, intestine and the kidneys in descending order (Onosaka and Cherian, 1982).  
 
 The levels of zinc in plasma are maintained at approximately 1mg/ml (Wise, 1995). The levels 
rise after administration of I.V. zinc and return to normal in 12 hours. Actinomycin D maintains 
the increase in plasma zinc for 24 hours (Richards and Cousins, 1975). 
 
Zinc as an antioxidant 
Zinc is redox inert in biological systems. The antioxidant effects of zinc do not fall clearly into 
the previously mentioned classifications. One of the factors that make it a unique in its 
antioxidant role is that there is no direct interaction ever shown between zinc and oxidant species 
(Powell, 2000). There are several proposed mechanisms, which attempt to explain the indirect 
antioxidant effects of zinc, some of which are as follows: 
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Possible mechanisms for the antioxidant effects of zinc 
Proposed mechanism Reference 
• Protection against vitamin E depletion (Bunk et al., 1989, Kim et al., 
1998) 
• Stabilization of membrane structure (Bray and Bettger, 1990) 
• Restriction of endogenous radical production (Bray and Bettger, 1990) 
• Essential structural component of the enzyme CuZnSOD (Marklund, 1982) 
• Maintenance of tissue concentrations of metallothionein (Cousins, 1985) 
• Stabilization of protein thiols (Gibbs et al., 1985) 
 
 
The antioxidant effects of zinc may be divided into acute and chronic effects (Powell, 2000). The 
acute effects of zinc supplementation are a consequence of the protection conferred to sulfhydrals 
and a reduction of redox active transition metals, such as iron and copper. The chronic effects of 
zinc supplementation include the induction of metallothioneins, a group of low molecular weight 
metal binding proteins. 
 
The antioxidant role of zinc attributed to its ability to bind and stabilize protein thiols was initially 
investigated in δ-aminolevulinate dehydratase, an enzyme that depends on its thiol groups for 
activity. The thiol groups were stabilized by Zn2+ and were found to be less prone to oxidation 
(Gibbs et al., 1985). 
 
Transition metals like iron and copper associate with high or low molecular weight cellular 
components such as nucleotides, peptides, proteins or DNA (Chevion, 1988, Czapski et al., 
1984). These associations form loci of bound metals undergoing repeated redox cycling of metals 
thereby inducing site-specific free radical generation (Chevion, 1988). By virtue of similarities in 
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coordination chemistry,  it is proposed that zinc can effectively compete with transition metals for 
critical binding sites (Cotton and Wilkinson, 1972). Experimental evidence supporting such 
antagonism is most clearly seen by the competition between zinc and copper for binding to heme 
proteins (Hegetschweiler et al., 1987). The displaced transition metals either bind to less critical 
sites or undergo hydrolytic polymerization in the cytosolic compartment (Spiro et al., 1967). Zinc 
has been noted to antagonize iron-mediated, xanthine/xanthine oxidase- induced peroxidation of 
RBC membranes (Girotti et al., 1986). Zinc has been established as a cardio-protective agent after 
myocardial ischemia. Perfusion of ischemic myocardium with a zinc-containing buffer induces 
the removal and excretion of copper from the myocardial tissue (Powell et al., 1999). This is 
associated with improvements in post-ischemic myocardial function and a reduction in the 
synthesis of ROS. 
 
Metallothioneins are low molecular weight proteins that are induced by the activation of metal 
responsive elements in by high environmental concentrations of zinc or other transition metals 
(Powell, 2000). Conditions of copper or cadmium overload can readily induce the displacement 
of zinc from these proteins and hence confer protection against their toxicity (Shaw et al., 1991). 
It is also proposed that metallothioneins are anti-apoptotic, an effect mediated by NFκB (Abdel-
Mageed and Agrawal, 1998). Rate constants measured for reactions between metallothioneins 
and reactive oxygen species (hydroxyl radicals and superoxide radicals) suggest a sacrificial 
oxidation of up to 20 cysteine sulphydral groups per molecule (Thornalley and Vasak, 1985). The 
sulphydral groups that are lost to ROS can be later regenerated by reducing agents like 
glutathione (Thornalley and Vasak, 1985, Abel and de Ruiter, 1989). 
 
Studies on zinc deficiency in both humans and animals have given us further insights into the 
importance of zinc as an antioxidant. Chronic zinc deficiency in rats is known to be associated 
with an increase in conjugated dienes and malondialdehyde production in the liver (Sullivan et 
 29
al., 1980). Experiments by Bray and collogues concluded that zinc deficiency evoked NADPH 
oxidase and cytochrome P450-induced increases in lipid peroxidation in both the lung and the 
liver (Bray et al., 1986). Other studies have demonstrated similar results in other tissues (Burke 
and Fenton, 1985, Oteiza et al., 1995). 
 
Finally zinc has an important role in the structure and stabilization of important antioxidant 
enzymes. Copper, zinc-superoxide dismutase catalyzes the dismutation of superoxide to oxygen 
and hydrogen peroxide. The latter and other hydroperoxides are subsequently reduced by the 
selenoenzyme glutathione peroxidase (GPx) (Klotz et al., 2003). 
 
Intracellular signaling and oxidative stress: the role of zinc 
Zn2+ is capable of inducing a stress response in terms of the stimulation of expansions when used 
for 1st time MTF-1 dependent transcription and activation of stress responsive signal cascades 
such as expansions when used for 1st time MAPK and PI3K/AKT. 
 
 
Zn deficiency-triggered oxidative stress could affect cell signaling, including (Powell, 2000): 
1. Transcription factors containing Zn finger motifs 
2. Other oxidant-sensitive transcription factors (NF-κB and AP-1). 
 
 The Zn finger motif in the Zn finger transcription factors is mainly a DNA-binding domain. 
Cysteine residues coordinate the Zn ion folding structural domains that participate in 
intermolecular interactions. Oxidative stress can impair the DNA-binding activity of Zn finger 
transcription factor, by oxidizing the cysteine residues and therefore altering the secondary 
structure of the protein (Oteiza and Mackenzie, 2005). 
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Furthermore zinc deficiency is associated with higher pro-oxidant levels that alter several signal 
transduction pathways. AP-1 and NFκB are activated by an increase in cellular oxidants in a 
background of zinc deficiency (Oteiza and Mackenzie, 2005). 
 
 
The role of zinc in regulating redox state 
Zinc/cysteine coordination environments in proteins are redox active. Oxidation of the sulfur 
ligands mobilizes zinc, while reduction of the oxidized ligands enhances zinc binding, providing 
redox control over the availability of zinc ions. Some zinc proteins are redox sensors, in which 
zinc release is coupled to conformational changes that control varied functions such as enzymatic 
activity, binding interactions and molecular chaperone activity. Whereas the released zinc ion in 
redox sensors has no known function, the redox signal is transduced to specific and sensitive zinc 
signals in redox transducers. Released zinc can bind to sites on other proteins and modulate signal 
transduction, generation of metabolic energy, mitochondrial function, and gene expression 
(Powell, 2000).  
Zinc and NSAID-mediated renal damage: 
Work done in the past at our laboratory has shown that indomethacin, when administered at a 
dose of 20mg/kg to male rats, is known to produce oxidative stress, alter membrane lipid 
composition and induce changes in the microscopic architecture of the kidney. Oxidative stress 
induced in the above manner was mitigated by L-arginine a nitric oxide donor (Basivireddy et al., 
2004). Mitochondrial dysfunction and altered balance of pro- and antioxidant enzymes have been 
proposed as possible mechanisms for these changes (Basivireddy et al., 2004, Varghese, 2006). 
Preliminary work done in our laboratory has shown that zinc, protected against such effects 
(unpublished data). It resulted in a reversal of pro-oxidant changes and increased the activities of 
antioxidant enzymes.  
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MATRIX METALLOPROTEINASES (MMPS) 
Matrix metalloproteinases are a group of proteins collectively referred to as matrixins that 
participate in the degradation of the extracellular matrix (ECM) (Visse and Nagase, 2003). In 
addition to the ECM, these proteases also degrade several other molecules that include hormones, 
growth factors, cytokines and other MMPs and hence contribute to the maintenance of the 
extracellular environment (Visse and Nagase, 2003, Folgueras et al., 2004). 
 
Structure of MMPs 
Shown below is the general structure of MMPs. 
 
Classification of MMPs 
This family consists of 44 different MMPs among which 23 are present in humans (Visse and 
Nagase, 2003, Folgueras et al., 2004). Sequence homology to collagenase 1 (MMP-1), the 
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cysteine switch motif, PRCGXPD that is essential to maintain the protein as an inactive zymogen, 
and the zinc-binding motif, HEXGHXXGXXH at the catalytic domain, are signatures used to 
assign proteins to this family. The only exception to this rule is MMP-23, which lacks the 
cysteine switch motif, but however maintains structural similarities to MMP-1 (Visse and Nagase, 
2003). 
 
Vertebrate MMPs can be divided into six groups based on substrate specificity, sequence 
similarity and domain organization as follows: 
 
I. Classification of MMPs based on substrate specificity and structural features 
Class MMPs Substrates and Structural Features 
Collagenases 1, 8, 13 and 18 Cleave collagens types I, II and III  
Gelatinases 
2 and 9 Denatured collagen, laminin and gelatin 
Fibronectin repeats in catalytic domain 
Stromelysins 3, 10, 11 proMMP-1 
Matrilysins 
7, 26 Lacks a hemopexin domain 
Pro-α-defensin, Fas-ligand, E-cadherin and pro-TNF-
α 
MT-MMPs 141, 151,161, 241, 
172 and 252 
ProMMP-2*, collagen type I, II, III 
1
 type-1 transmembrane proteins 
2
 GPI anchored proteins 
Other MMPs 12, 20,22, 23, 28 Elastin, amelogenin 
*All members of MT-MMP class except MT-MMP-4; MT-MMP: Membrane type MMP 
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Gelatinases 
The key focus of this study rests on the gelatinases, MMP-2 and MMP-9. They are zinc- 
dependent endopeptidases, which are involved, in a wide variety of physiological and 
pathological processes (Lelongt et al., 2001, Visse and Nagase, 2003). 
 
MMP-2 and MMP-9 are similar in terms of structure and substrate specificity. The nascent 
gelatinases have a N-terminal signal sequence called as the pre -domain that directs the protein to 
the endoplasmic reticulum. The pre-domain is followed by a pro-domain that maintains enzyme 
latency. Cleavage of the pro-domain exposes the catalytic domain that contains cysteine repeats, 
collagen II binding fibronectin type II inserts and a conserved zinc-binding region. The catalytic 
regions are connected by a hinge region to four hemopexin-like domains that, among other things, 
mark the enzyme for specific tissue inhibitor of metalloproteinase (TIMP) recognition. The 
gelatinases share a wide array of substrates, which include basement membrane components such 
as type IV and type V collagens, aggrecan, elastin and gelatins (denatured collagens), as well as 
non-basement membrane proteins, such as IL-1β, substance P, mylein basic protein, amyloid β 
peptide and pro-transforming growth factor β (Lelongt et al., 2001). Cleavage of non-basement 
membrane proteins is more so with MMP-9 than MMP-2. Both MMP-2 and MMP-9 require zinc 
and calcium for their activity and bind at a ratio of 2 zinc and 3 calcium ions per subunit (Lelongt 
et al., 2001, Visse and Nagase, 2003). 
 
MMP-2 and MMP-9 show differences in molecular weight, expression patterns, regulation, 
inhibition by TIMP and pathways of activation. This is the basis for differences in the gelatinase 
profiles observed in different pathologies (Lelongt et al., 2001). The differences between the two 
gelatinases MMP-2 and MMP-9 are highlighted in the table below. 
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Gelatinases and their Characteristics 
Characteristics MMP-2 MMP-9 
Synonyms • EC 3.4.24.24 
• 72 kDa gelatinase 
• Gelatinase A 
• EC 3.4.24.35 
• 92 kDa gelatinase 
• Gelatinase B 
Gene location (Humans) 16q13-q21 20q11.2-q13.1 
Molecular Weight (pro-forms) 72kD 92kD 
Molecular Weight (active forms) 64kD 82, 67 and 64kD 
Co-factors 
 
4 Ca and 2 Zn ions per 
subunit 
3 Ca and 2 Zn ions per 
subunit 
Activators MT-MMP, trombin, 
urokinase 
Cathepsin, trypsin, α-
chymotrypsin, stromelysin, 
colalgenase-I, matrilysin, 
mast cell chymase, MMP-2, 
trypsin 
Regulation Mainly post-transcriptional Mainly transcriptional 
Expression in the kidney Constant low level 
expression 
Highly inducible 
 
Regulation of gelatinases 
Transcriptional regulation:  
One of the remarkable features of matrixins is the inducible nature of many of their genes. 
Studies on the promoter region of MMP-9 reveal motifs that are homologous to the binding sites 
for activator protein-1 (AP-1), PEA3/ets, NF-kB and transcription factor SP-1(Sato and Seiki, 
1993). Induction of MMP-9 gene transcription has been observed with 12-O-tetradecanoyl-
phorbol-acetate and tumor necrosis factor (TNF) alpha (Sato and Seiki, 1993). Ultravoilet B 
irradiation up-regulates MMP-9 expression in human dermal fibroblasts (Kut et al., 1997). This 
was reported to be a consequence of activation of stress-activated protein kinase (JNK-2) through 
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the generation of reactive oxygen species and lipid peroxidation by the ion-driven Fenton reaction 
(Wang and Kochevar, 2005). 
 
Other mechanisms of gelatinase induction include increased MMP-9 mRNA stability induced by 
transforming growth factor-beta1 (TGF-1) (Sehgal and Thompson, 1999), stabilization of the pro 
enzyme form of MMP-2 by TGF-1 (Sehgal and Thompson, 1999) and regulation of translational 
efficiency (Jiang and Muschel, 2002). 
 
Proenzyme activation:  
MMPs can be activated by proteinases in vivo or by chemical agents such as thiol-modifiying 
agents (4-aminophenylmercuric acetate, HgCl2 and N- ethylmaleimide), oxidized glutathione, 
SDS, chaotropic agents and reactive oxygen species in vitro (Visse and Nagase, 2003). These 
agents are thought to act by disturbing the cysteine zinc interaction of the cysteine switch 
following which the propeptide segments are removed in a stepwise manner (Van Wart and 
Birkedal-Hansen, 1990). 
 
ProMMP-2 is resistant to activation by general proteinases. The major pathway of activation of 
proMMP-2 takes place on the cell surface and is mediated by membrane type matrix 
metalloproteinases (MT-MMPs) (Visse and Nagase, 2003). All members of the MT-MMP family 
except MT-MMP4 have been demonstrated to activate proMMP-2. Studies show that the 
activation of proMMP-2 requires both active MT-MMP-1 and TIMP-2 bound MT-MMP-1. The 
TIMP-2 bound MT-MMP-1 acts as a receptor for proMMP-2 (Butler et al., 1998). Pro-MMP-2 
binds to the free C-terminal domain of TIMP-2 through its hemopexin domain that is assumed to 
localize it near an active MT-MMP-1 (Wang et al., 2000). 
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Plasmin is an important activator of proMMP-9 in vivo (Pepper, 2001, Kaur et al., 2004, Lijnen, 
2001). Plasmin is generated from plasminogen by tissue plasminogen activator bound to fibrin 
and urokinase type plasminogen activator bound to a specific cell receptor (Pepper, 2001). The 
membrane localization of both plasminogen and urokinase plasminogen activator assists localized 
pro-MMP activation and ECM turnover (Pepper, 2001, Collen, 2001). MMP-2 is also activated 
by the cell surface associated uPA /plasmin system, whereas soluble plasmin degrades it 
(Mazzieri et al., 1997). 
 
MMP-3 can activate proMMP-9, and MMP-3 and MMP-10 can super activate procollagenase, 
thereby generating collagenase with higher specific activity (Knauper et al., 1993, Nagase, 1997).  
 
Inhibitors:  
Inhibitors of MMP activity may be classified as endogenous inhibitors like tissue inhibitors of 
metalloproteinases (TIMPs), which are specific inhibitors of MMPs, and as exogenous inhibitors 
like drugs, which act by chelating Ca2+ and Zn2+. The tetracycline group of antibiotics, for 
example, inhibits MMP activity by virtue of its chelating ability, a property that is entirely 
distinct from their antibacterial actions (Woessner, 1999). 
 
Some of the other important, but non-specific, inhibitors of MMP activity include tissue factor 
pathway inhibitor-2 (TFPI-2), thrombospondin 1 and 2, alpha-2 macroglobulin and reversal-
inducing cysteine rich protein with Kazal motifs (RECK) (Visse and Nagase, 2003). TFPI-2 is a 
serine protease inhibitor that shares structural a homology with TIMP and inhibits MMP-1, -2, -9 
and –13. TFPI appears to bind and co-precipitates with MMPs suggesting sequestration as a 
possible mechanism (Herman et al., 2001).  
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Thrombospondin-2 can regulate MMP-2 by forming a complex that facilitates scavenger- 
receptor mediated endocytosis. Similarly, thrombospondin-1 has been shown to inhibit the 
activation of MMP-2 and MMP-9 pro-forms and also to modulate MMP-2 production (Egeblad 
and Werb, 2002). Alpha-2-macroglobulin is a 772kD plasma proteinase inhibitor synthesized 
mainly in the liver by hepatocytes. Even though TIMPs are present, α2-macroglobulin is thought 
to be the major MMP inhibitor in plasma. The mechanism of inactivation of MMPs by α2-
macroglobulin involves the presentation of a cleavable bait region to the MMP which, when 
proteolytically cleaved, traps the proteinase within the α2-macroglobulin that later becomes 
covalently attached by transacylation (Baker et al., 2002). RECK is an 110kD glycoprotein that 
contains serine -proteinase-inhibitor -like domains and associates with the cell membrane through 
a GPI anchor. It is widely expressed in normal human tissues but its levels appear to be low in 
several tumor cell lines. Over-expression of RECK has been shown to post-transcriptionally 
downregulate MMP-9 and inhibit the cellular activation of MMP-2. RECK-/- mice that die at 
E10.5 and show severe disruption of mesenchymal tissue and organogenisis underline the 
importance of this protein (Oh et al., 2001). However, embryos of RECK-/-, MMP-2-/- double 
knock-out mice show improved vascular development, larger body size and survive till E11.5 (Oh 
et al., 2001). 
 
 
Tissue inhibitor of matrix metalloproteinases (TIMPs): 
The tissue inhibitors of metalloproteinases, thus far, consist of four family members, TIMP-1, 
TIMP-2, TIMP-3 and TIMP-4. TIMPs inhibit the activity of MMPs by forming tight non-
covalent complexes in a 1:1 stoichiometric ratio with MMPs (Visse and Nagase, 2003). 
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TIMPs are smaller proteins in comparison to the MMPs and have molecular weights ranging from 
21 to 29 kDa and are variably glycosylated (Brew et al., 2000). Structurally, TIMPs are cysteine-
rich proteins, which contain three disulphide bonds. They are generally compromised of two 
domains, the larger N-terminal domain associated with MMP inhibition and a smaller C-terminal 
domain (Brew et al., 2000, Visse and Nagase, 2003). The characteristics of individual members 
of the TIMP family are given in the table below. 
 
 
Characteristics of members of the TIMP family 
Characteristics TIMP-1 TIMP-2 TIMP-3 TIMP-4 
Synonyms Erythroid-
potentiating activity 
 
Fibroblast 
collagenase inhibitor 
CSC-21K 
 
Protein MIG-5 
 
Cardiac inhibitor 
of 
metalloproteinase 
 
Length of peptide 207 AA 220 AA 211 AA 224 AA 
Molecular weight 28kD 21kD 24/27kD 22kD 
Gelatinase 
inhibition 
Pro-MMP-9 Pro-MMP-2 Pro-MMP-2&9 Pro-MMP-2 
Localization Soluble Soluble/Cell 
surface 
ECM Soluble/Cell 
surface 
N-glycosylation 
sites 
2 0 1 0 
 
TIMP-1 and TIMP-2 are the best-characterized members in this family. These have erythroid-
potentiating activity, growth stimulating effects and regulate development and apoptosis in 
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various cells in addition to its MMP inhibiting effects (Stetler-Stevenson et al., 1992, Hayakawa 
et al., 1992, Barasch et al., 1999). 
 
Gelatinases and the kidney 
The expression profiles of MMPs and TIMPs in the kidney are complex and species dependent. 
MMP-2, -3, -9, -13, -14, -24, -25, -27, -28 and TIMP-1, -2, and -3 are all expressed in the kidney 
(Catania et al., 2007).  
 
The profile of gelatinase expression in the kidney has been well characterized in both rats and 
humans. MMP-2 is the major gelatinase expressed in the glomerulus, proximal tubules and distal 
tubules in most species, including rats (Tomita et al., 2004, Inkinen et al., 2005, Schaefer et al., 
1996). The expression of MMP-9 is confined to the glomerulus and initial parts of the PCT 
(Inkinen et al., 2005, Schaefer et al., 1996, McMillan et al., 1996). 
 
TIMP-1 is expressed in the glomerulus in both humans and rats (Tomita et al., 2004). There is no 
clear evidence as yet about the normal pattern of expression of TIMP-2 and TIMP-3 in normal rat 
kidneys (Catania et al., 2007). 
 
The role of MMPs in acute kidney injury in pathologies related to oxidative stress, such as 
ischemia-reperfusion, has been experimentally established previously (Ziswiler et al., 2001). 
Studies with a single dose of 30mg/kg BB-94, a broad spectrum MMP inhibitor, reduced 
proteinuria (Ermolli et al., 2003) but not the increase in serum creatinine associated with 
ischemia-reperfusion injury (Ziswiler et al., 2001). MMP-2 and -9 were increased in renal tubules 
and in the interstitium after 1 to -3 days of reperfusion, following 52 min of ischemia in rats 
(Basile et al., 2004). Other studies with 30 minutes of ischemia followed by 60 minutes of 
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reperfusion were also associated with increased expression of MMP-2 and -9 and TIMP-2 in 
glomeruli, and a decrease in TIMP-1 (Caron et al., 2005). 
 
Gelatinases and NSAIDs 
Anti-inflammatory agents, such as indomethacin, have been used to reduce invasion of cancer 
cell lines (Ackerstaff et al., 2007, Diament et al., 2006, Wang et al., 2005) . Cells over-expressing 
COX-2 acquire increased invasiveness and angiogenic ability by activation of vascular 
endothelial growth factor (VEGF), urokinase like plasminogen activator (uPA) and matrix 
metalloproteinase-2 (MMP-2). NS-398 and indomethacin are known to inhibit these effects (Li et 
al., 2002). NSAIDs are also known to suppress ERK/Sp-1 mediated transcription which in turn 
results to decreased MMP-2 transcription (Pan and Hung, 2002). 
 
Indomethacin is also known to prolong gestation in rabbits by decreasing MMP-2 and –9 
activities and increasing TIMP-1 levels in the cervix (Fortson et al., 2006). Studies also 
demonstrate induction of MMP-9 by urokinase-type plasminogen activator (uPA) in THP-1 
monocytes is via a pathway involving MEK1-ERK1/2-mediated activation of cytosolic PLA2 and 
eicosanoid generation. This suggests an important role for ecosinoids in monocyte activation and 
migration induced by uPA and MMP-9, an effect that can be inhibited by NSAIDs (Menshikov et 
al., 2006). 
 
Indomethacin toxicity is associated with gastric ulceration. This process is mediated by reactive 
oxygen species and is associated with a reduction in MMP-2 transcription and translation both of 
which are reversed by antioxidants such as melatonin (Ganguly et al., 2006) . Data on the role of 
MMPs in NSAID-mediated renal toxicity is scarce. 
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Gelatinases and oxidative stress 
Treatment of mesangial cells with pro-inflammatory cytokines resulted in an increase in the 
biosynthesis of NO and superoxide, the precursors of the highly potent pro-oxidant ONOO-, and 
an associated increase in MMP-2 activity (Okamoto et al., 1997). It has also been demonstrated 
that superoxide, hydrogen peroxide or ONOO- could enhance gelatinolytic activity of unpurified 
MMP-2 derived from smooth muscle cells and their media (Rajagopalan et al., 1996). Similar 
experiments with hydrogen peroxide or superoxide generating systems in cultured rat fibroblasts 
showed enhanced activity of MMP-2, -9, and –13 (Siwik et al., 2001). Superoxide is believed to 
play a greater role than NO in this process as elimination of the former failed to activate purified 
form of MMP-8 (Rajagopalan et al., 1996). 
 
The mechanism of activation of MMPs by reactive oxygen and nitrogen species is thought to 
involve the oxidation of sulfhydryl groups located on cysteine residues that form the 
autoinhibitory peptide domain, thus influencing its interaction with the coordinated  Zn2+ at the 
catalytic site (Owens et al., 1997). This could result in changes that may induce, modulate or 
inhibit enzyme activity in response to the redox state within the cell (Owens et al., 1997). 
 
The exact nature of post-translational modifications of MMPs resulting in their activation or 
inactivation still remains a matter of debate. Experiments have shown that minimal 
concentrations of ONOO- (1-20µM) activate MMP-1, -8 and –9 without removal of the 
autoinhibitory pro-peptide domain (Schulz, 2007). In the presence of normal cellular levels of 
glutathione, ONOO- causes S-glutathiolation of the cysteine-containing PRCGVPD sequence 
within this domain resulting in activation of the enzyme and a modification of its size, that is 
difficult to detect on standard SDS PAGE but may be detected by autoradiography or mass 
spectrometry (Okamoto et al., 2001). In contrast, higher concentration of ONOO- is known to 
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inactivate MMP-2 activity, possibly by nitration of tyrosine residues in the sequence. Similar 
studies on MMP-9 show an increase in enzyme activity coinciding with evidence of S-
nitrosylation of the pro-peptide domain on mass spectrometry (Gu et al., 2002). Mass 
spectrometric analysis of MMP-2 on exposure to 3mM ONOO- have shown other extensive 
modifications, such as glutathiolation of Cys-65 and Cys-102, hydroxylation of Phe-583 and 
nitration of Tyr-244. In addition to activation of the enzyme, exposure to ONOO- may also alter 
the structural binding characteristics of cysteine-rich TIMPs, thus favoring an increase in MMP 
activity (Frears et al., 1996). 
 
Zinc and MMPs 
Matrix metalloproteinases are zinc-dependent endoproteinases. The zinc ion is present at the 
catalytic site and is essential for activity. Chelation of zinc causes an inhibition of MMP activity, 
which returns to normal in the presence of excess zinc (Boissier et al., 2000, Springman et al., 
1995). These tests were, however, done in cancer cell lines, which were able to achieve high 
intracellular zinc concentrations as compared to normal cells. 
 
Studies with cell lines indicate that zinc is able to suppress invasiveness of cell lines like PC-3 
and SKRC-1 effectively. However, there was no effect on LNCaP cells. Zinc was found to 
effectively inhibit aminopeptidase and urokinase-type plasminogen activator (Ishii et al., 2001). 
These substances are known activators of MMPs.  Zinc causes no changes in the activity of 
purified MMPs (Ishii et al., 2001). 
 
• The interactions between MMPs and zinc have been only explored with reference to its 
structural importance. Studies evaluating the indirect effects of zinc on MMPs are still limited 
and lie unexplored. 
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•  
• Hypothesis 
Indomethacin has been shown to alter microscopic architecture and induce oxidative 
stress in the kidney. Zinc has been shown to play a protective role against the above-
mentioned changes. In view of these effects, we hypothesize that indomethacin-induced 
oxidative stress alters matrix metalloproteinase-antiproteinase balance in the rat kidney. 
We further hypothesize that zinc, by virtue of its antioxidant effects, may confer a 
protective effect in the maintenance of this balance. 
 
• Aims and Objectives 
This study has been designed to achieve the following aims and objectives: 
1. To study the effect of indomethacin on the activity of metalloproteinases (MMP) in the 
kidney of rats 
2. To study the effect of indomethacin on the activity of tissue inhibitors of 
metalloproteinases (TIMP) in the kidney of rats 
3. To assess the role of indomethacin -induced oxidative stress in the kidney in altering the 
renal protease-antiprotease balance. 
4. To evaluate the effect of zinc in protecting against such effects. 
5. To evaluate the collective effects of these alterations on renal function. 
 
 
 
 
 
 
 
MATERIALS 
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The following chemicals have been used to carry out this thesis work: 
1-[p-Chlorobenzoyl]-5-methoxy-2-methylindole-3-acetic acid (indomethacin), 
acrylamide, ammonium persulfate, anti β-actin antibody, β-mercaptoethanol, bis-
acrylamide, Tetrabromophenolsulfonephthalein (bromophenol blue), color burst 
molecular weight markers, N, N, N`, N`-tetramethyl-ethylenediamine (TEMED), sodium 
dodecyl sulphate   were obtained from Sigma –Aldrich Chemicals, St. Louis U.S.A. 
Calcium chloride, hydroxymethyl aminomethane hydrochloride (TRIS HCl), glycine, 
polyethylene glycol-4-tert-octylphenol ether (Triton X 100), sodium chloride, obtained 
from Sisco Research Laboratories (SRL) Pvt. Ltd., Mumbai. 
Methanol was obtained from Qualigens fine chemicals. 
1-butanol, gelatin, glacial acetic acid was obtained from E. Merck (India) Ltd. 
Zinc sulphate was obtained from Sarabai Merck Ltd.  
Polyoxyethylene monolauryl ether (Brij 35) was obtained from ICI America Inc. 
Skimmed milk powder was obtained from Amul Corp. India 
Anti-MMP-2, anti-MMP-9, anti-TIMP-1 and anti-TIMP-2 antibodies were obtained from 
Lab Vision Corp. U.S.A 
Halothane IP (Fluothane) was obtained from Nicholas Parimal India Ltd. 
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• METHODOLOGY 
Animals 
Male albino Wistar rats from the licenced animal house of the institution, weighing 
between 180-240 grams, were used for this study. The animals were fed with a 
commercially available standard rat chow diet (“Amrut” brand supplied by Sai Durga 
Feeds and Food). The animals were exposed to 12 hour light-dark cycle. The animals had 
free access to drinking water and food. The Committee for the Purpose of Control and 
Supervision of Experimentation on Animals (CPCSEA), Government of India, approved 
the experimental protocol (CPCSEA) (IAEC No 2/2006).  
 
Drug dosage and preparation 
Indomethacin was used at a dose of 20mg/kg body weight. The dose of indomethacin was 
calculated based on the weight of the animal. It was then dissolved in 1ml of 5% (w/v) 
sodium bicarbonate in distilled water by gentle warming. 
 
Zinc sulphate was used at a dose of 50mg/kg body weight. The required dose of the drug 
was calculated based on the weight of the animal. It was then dissolved in 1ml of distilled 
water. 
 
Protocol for drug administration 
Protocol for indomethacin dose response studies: Experiments were done with batches 
containing five animals each, which were matched for age and weight. The control group 
was adminstered the veichle (5% bicarbonate) only. The other four animals in the group 
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were treared with increasing doses of indomethacin ranging from 10mg/kg to 60mg/kg 
respectively. All animals were sacrificed 24 hours later. 
Protocol for indomethacin dose-response studies 
II. Time III. Treatment 
0hr 
Control 
5% 
HCO3- 
Indo 
10mg/kg 
Indo 
20mg/kg 
Indo 
40mg/kg 
Indo 
60mg/kg 
24hr Sacrifice Sacrifice Sacrifice Sacrifice Sacrifice 
 
Protocol to assess the effects of zinc: All experiments were done with batches of four 
rats each. The animals in each batch had similar weights and were separated into four 
groups designated as Control (group 1), Indo (group 2), Indo+Zn (group 3) and Zn alone 
(group 4) respectively. 
Protocol to assess the effects of zinc 
Treatment group Time (hr) 
 -2hr 0hr 24hr 
Control Water 5% bicarbonate Sacrifice 
Indo Water Indomethacin (20mg/kg) Sacrifice 
Indo+Zn Zinc (50mg/kg) Indomethacin (20mg/kg) Sacrifice 
Zn Zinc (50mg/kg) 5% bicarbonate Sacrifice 
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In all the experiments, the animals were fasted overnight. Animals in-group 3 and 4 were 
pretreated with zinc sulfate 50mg/kg body weight by gavage, where as the remaining two 
groups received an equal volume of the vehicle (water). 2 hours subsequently groups 2 
and 3 were administered indomethacin at a dose of 20mg/kg body weight by oral gavage 
where as group’s 1and 4 received only the vehicle (5% bicarbonate). 
 
 Processing of tissue 
The animals were sacrificed by cervical dislocation, 24 hours later, under halothane 
anesthesia. Blood was drawn from the heart for estimation of serum urea and creatinine. 
Both kidneys were removed, decapsulated, washed with ice cold saline. cut into equal 
hemi-sections and snap-frozen in liquid nitrogen. The snap-frozen samples were kept at –
70°C until further processing. 
 
Experiments done using kidney homogenate 
 
Preparation of renal homogenate 
Snap-frozen renal tissue was washed twice with ice-cold saline and was minced into 
small pieces, using a pair of sharp scissors. The minced tissue was immediately 
homogenized in 2ml of homogenization buffer, containing 50mM Tris-HCl, sodium 
chloride and protease inhibitor PMSF (pH 7.4) (Heo et al., 1999) using a Potter-Elvehjem 
homogenizer at 7000 rpm for 1 minute (8-10 strokes). Renal homogenate obtained from 
the above process was centrifuged at 13,500g at 4oC for 30 minutes to remove suspended 
cellular debris. The supernatant was used for zymography, reverse-zymography and 
western blots. 
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Gelatin zymography: 
Supernatants from renal homogenates were loaded, at a standard concentration of 200µg 
protein per well, into 10% polyacrylamide gel containing 0.1% gelatin (Basile et al., 
2004) and electrophoresed at 4°C. The gel was removed from the cassette and washed 
three times (30minutes each) with the wash buffer (2.5% triton X 100) at 4°C. The gel 
was then washed twice with water and incubated in a development buffer (50 mM Tris, 
pH 7.5, 200 mM NaCl, 5 mM CaCl2, and 0.02% Briji-35) for 16-18 hours at 37°C. Each 
gel was stained with 0.5% Coomassie blue G-250 in 30% methanol and 10% acetic acid 
for 40 minutes and destained for 15 minutes in 30% methonal/10% acetic acid. MMP 
activity was detected as areas of clearing in the gel, where the gelatin had been cleaved 
by the MMPs. The gels were digitized using a CCD frame digitizer system (Alpha-
Innotech) and densitometric analysis of the cleared zones was done using AlphaEaseFC 
(Alpha-Innotech). Positive controls for MMP-2 and 9 were obtained from conditioned 
culture medium used for growing HT 1080 cell (human fibrosarcoma) (Inkinen et al., 
2005). Medium was collected after 2-3 days of growth when the cells attained confluence 
and used as sources of MMP-2 and -9. 
 
Protein quantification by Western blotting: 
Supernatants from renal homogenates, containing 40µg protein, were denatured in the 
protein dissociation buffer containing 62.5mM Tris-HCl, 2% SDS, 10% glycerol, 0.004% 
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bromophenol blue and 5% β-mercaptoethanol for 5 minutes at 95°C, separated on 12% 
polyacrylamide gel at 200V and electroblotted to nitrocellulose membranes at 250 mA 
(Maric et al., 2004). The membranes were incubated in primary antisera and subsequently 
developed as per the manufacturer’s protocol. The protein bands on the membranes were 
then digitized using a CCD frame digitizer (Alpha Innotech) and the bands were 
quantified by densitometry using the gel documentation system AlphaEaseFC (Alpha 
Innotech). 
 
Estimation of protein: 
Protein was estimated by the method described by Lowry’s method (Lowry et al., 1951). 
This method involves the pre-treatment of protein with alkaline copper sulphate in the 
presence of tartrate followed by addition of Folin’s phenol reagent (a mixture of 
phosphomolybdic-tungstic acids), which is reduced by the chelated protein. This results 
in the production of a characteristic blue colour that is measured spectrophotometrically 
at 660nm. 
Reagents:   
1. Lowry’s reagent 
2. Folin’s reagent (diluted 1:1 with deionized water). 
Assay: Samples were diluted 1:10 and added in volumes of 25 and 50µl. 2.5 ml of 
freshly prepared Lowry’s reagent was added and the total volume was made up to 3 ml 
with deionized water. After incubating at room temperature for 10 minutes, 0.25 ml of 
Folin’s phenol reagent was added. The blue colour produced was measured 
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spectrophotometrically at 660nm after incubating at room temperature for a further 30 
minutes. 
 
IV. Estimations in serum 
Collection of blood from animals: 
Blood (2ml) was collected by cardiac puncture after cervical dislocation in anesthetized 
animals that were sacrificed for removal of kidneys. Blood samples were allowed to clot 
for 30 minutes at room temperature and then centrifuged to separate out the serum. The 
serum samples were stored in airtight containers at –20°C for further analysis. 
 
Blood (0.1ml) was collected by tail end sectioning in anesthetized animals for studies, 
which required repeated sampling.   
 
Estimation of blood urea: 
Blood urea levels were estimated using Infinity™ Urea single liquid stable reagent 
(Thermo Fisher Scientific, Inc.). 
 
Estimation of serum creatinine: 
The creatinine assay was based on the Jaffe’s reaction in a protein free filtrate obtained 
from serum (Brod and Sirota, 1948). As the volumes of blood obtained from animals 
were small, the volumes in the above assay were modified to enable estimation in a 
ELISA plate reader. Proteins were precipitated by adding 60µl of deionized water, 20µl 
of 10% sodium tungstate and 40µl of 2/3N sulphuric acid to 40µl of serum. A protein- 
free filtrate was obtained as a supernatant by centrifugation of the above-mentioned 
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mixture at 3500 rpm for 5 minutes. 40 µl of working reagent (1:1 mixture of 0.004M 
picric acid and 0.75N NaOH) was added to 60 µl of protein free filtrate in a microtitre 
plate. The intensity of colour generated by the reaction was measured, using a Bio-Rad 
ELISA plate reader at a wavelength of 490nm. Serum creatinine was calculated on 
comparison with a 1mg% standard using the formula: 
 
V. Serum creatinine (mg/dl) = Absorbance of test/ Absorbance 
of standard x 4 
 
The precision of the above assay was established by plotting a standard graph and the 
accuracy was evaluated by using quality control samples obtained from the external QC 
program, Department of Clinical Biochemistry CMC Vellore. 
 
VI. Statistical analysis 
Data obtained from treated animals were compared with those from control animals. For 
the zymogrmas and Western blots, the bands from control animals were normalized with 
reference to the control. Statistical significance was calculated both within groups and 
between groups by perfoming a one way analysis of variance (ANOVA) with 
Bonferroni’s as a posthoc test, using SPSS, version 11.0.A p value of less than 0.05 was 
taken to indicate statistical significance.   
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RESULTS 
Renal homogenates from rats showed pro-MMP-9 (92kD), pro-MMP-2 (72kd) and 
MMP-2 (65kd) activity. 
1. Studies on proMMP-9 
1.1. Effect of varying doses of indomethacin on pro-MMP-9 activity in rat kidney, 24 
hours after the dose of the drug 
Preliminary zymogram studies showed an initial increase in pro-MMP-9 activity, 
followed by a decrease in activity with increasing doses of indomethacin. Maximal 
activity was seen at a dose of 20mg/kg (Figures 1A and 1B). 
 
 
 
 
 
 
 
 
Figure 1A: Gelatin zymogram showing dose-dependent changes in 
proMMP-9 activity in response to indomethacin. Animals were treated 
with various doses of indomethacin and sacrificed 24 hours later. This is a 
representative zymogram showing MMP-9 activity (white bands), as 
assessed by gelatin zymography, using a 10% poly-acrylamide gel, 
loading 100 µg renal homogenate protein per lane. The samples were 
obtained from control (0mg/kg indomethacin) and indomethacin-treated 
(10mg/kg to 60mg/kg) animals.  
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Figure 1B: Dose-dependent changes in pro-MMP-9 activity in response to 
indomethacin. Data are means of activity of pro-MMP-9 (± standard error 
of mean (SEM), obtained by image analysis, with the activity of the 
controls set at one.  
 
 
 
 
 
1.2. Effect of varying doses of indomethacin on pro-MMP-9 protein levels in rat 
kidney, 24 hours after the dose of the drug 
Western blot studies done with renal homogenates from animals given various doses of 
indomethacin showed that the drug did not produce any significant effects on levels of 
pro-MMP-9 protein (Figure 2A and 2B). 
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Figure 2A: Western blot showing effects of various doses of 
indomethacin on protein expression of proMMP-9 in renal homogenates, 
24 hours after the drug. This is a representative blot, using a 10% poly-
acrylamide gel, with 25 µg of protein loaded per lane. β-actin was used as 
a protein loading control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2B: Effects of various doses of indomethacin on protein 
expression of pro-MMP-9 in renal homogenates, 24 hours after the drug. 
Preliminary data shown here represent mean expression levels of pro-
MMP-9 protein (± standard error of mean (SEM), n=2) obtained by image 
analysis of Western blots, with the activity of the controls set at one.  
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1.3. Effect of zinc pretreatment on indomethacin-induced effects on pro-MMP-9 in 
rat kidney, 24 hours after administration of indomethacin: 
Indomethacin (at 20 mg/kg) was found to significantly increase pro-MMP-9 activity in 
the renal homogenates, as compared to the control groups (p value=0.012). Pretreatment 
of the animals with zinc did not produce any significant effect on the drug-induced 
increase in pro-MMP-9 activity (Figure 3). The protein levels of pro-MMP-9 were also 
not affected by the zinc pretreatment, either alone or with indomethacin (Figures 3A and 
3B and Figures 4A and 4B). 
 
 
 
 
 
 
 
 
Figure 3A: Pro-MMP-9 (92kD) activity in renal homogenates, 24 hours 
after administration of 20mg/kg indomethacin, as assessed by gelatin 
zymography using a 10% poly-acrylamide gel, loading 100 µg protein per 
lane. The samples were from animals in the control, indomethacin-treated 
(Indo), zinc-pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) 
only groups. HT-1080 cell line-conditioned media serves as a positive 
control for pro-MMP-9.   
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Figure 3B: Pro-MMP-9 (92kD) activity in renal homogenates. The 
samples were from animals in the control, indomethacin-treated (Indo), 
zinc-pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) only 
groups. Data are means of activity of pro-MMP-9 (± SEM), obtained by 
image analysis of zymograms, with the activity of the controls set at one.  
* indicates p<0.05 as compared to control group;  n=6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4A: Relative concentrations of pro-MMP-9 in renal homogenates, 
24 hours after indomethacin (20mg/kg) administration, as assessed by 
Western blot using a 10% poly-acrylamide gel, loading 25 µg protein per 
lane. The samples were from animals in the control, indomethacin-treated 
(Indo), zinc-pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) 
only groups (n=5 in each group). This shows a representative blot with 
pro-MMP-9 (92kD) bands. β-actin bands show equal protein loading in all 
lanes. 
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Figure 4B: Relative concentrations of pro-MMP-9 in renal homogenates, 
24 hours after indomethacin (20mg/kg) administration, as assessed by 
Western blot. Data represents means of pro-MMP-9 protein levels (± 
SEM), obtained by image analysis of Western blots, with the 
concentration of the controls set at one. 
 
 
2. Studies on pro-MMP-2 
2.1. Effect of varying doses of indomethacin on pro-MMP-2 activity in rat kidney, 24 
hours after the dose of the drug  
Preliminary zymograms showed an initial rise in pro-MMP-2 activity, followed by a drop 
in activity with increasing doses of indomethacin. The maximal activity was noted at a 
dose of 10mg/kg at 24 hours (Figures 5A and 5B).  
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Figure 5A: Gelatin zymogram showing dose-dependent changes in pro-
MMP-2 activity in response to indomethacin. Animals were treated with 
various doses of indomethacin and sacrificed 24 hours later. This is a 
representative zymogram showing MMP-2 activity (white bands), as 
assessed by gelatin zymography, using a 10% poly-acrylamide gel, 
loading 100µg renal homogenate protein per lane. The homogenates were 
obtained from control (0mg/kg indomethacin) and indomethacin-treated 
(10mg/kg to 60mg/kg) animals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5B: ProMMP-2 activity in renal homogenates in response to 
varying doses of indomethacin. Data are means of pro-MMP-2 activity 
(±SEM), n=2, obtained by image analysis of zymograms, with the activity 
of the controls set at one.   
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2.2. Effect of varying doses of indomethacin on pro-MMP-2 protein levels in rat 
kidney, 24 hours after the dose of the drug 
Western blots done to assess changes in pro-MMP-2 protein levels in response to 
increasing doses of indomethacin showed that there were no significant changes in the 
levels of protein with the different doses (Figure 6A and 6B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6A: Western blot showing effects of various doses of 
indomethacin on protein expression of pro-MMP-2 in renal homogenates, 
24 hours after dosing. This is a representative blot, using a 10% poly-
acrylamide gel, with 25 µg of protein loaded per lane. β-actin was used as 
a protein loading control. 
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Figure 6B: Pro-MMP-2 activity in renal levels in response to varying doses of 
indomethacin. Data are means of pro-MMP-2 levels (±SEM), n=2, obtained by 
image analysis of western blots, with the activity of the controls set at one. 
 
 
 
 
 
2.3. Effect of zinc pretreatment on indomethacin-induced effects on pro-MMP-2 in 
rat kidney, 24 hours after administration of indomethacin 
Pretreatment with zinc did not result in any significant changes in indomethacin-induced 
changes in pro-MMP-2 activity (Figures 7A and 7B) or protein levels (Figures 8A and 
8B).  Treatment with zinc alone did not affect either the activity or protein content of 
proMMP-2. 
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Figure 7A: Pro-MMP-2 (72kD) activity in renal homogenates, 24 hours after 
administration of 20mg/kg indomethacin, as assessed by gelatin zymography 
using a 10% poly-acrylamide gel, loading 100 µg protein per lane. The 
samples were from animals in the control, indomethacin-treated (Indo), zinc-
pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) only groups. HT-
1080 cell line-conditioned media servesd as a positive control for pro-MMP-
2.   
 
 
 
 
 
Figure 7B: Pro-MMP-2 (72kD) activity in renal homogenates. The 
samples were from animals in the control, indomethacin-treated (Indo), 
zinc-pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) only 
groups. Data are means of activity of pro-MMP-2 (± SEM), obtained by 
image analysis of zymograms, with the activity of the controls set at one; 
n=6.
Pro-MMP-2 activity
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
Control Indo Indo+Zn Zn
R
e
la
tiv
e
 
a
c
tiv
ity
 62
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8A: Relative concentrations of pro-MMP-2 (72kD) in renal 
homogenates, 24 hours after indomethacin (20mg/kg) administration, as 
assessed by Western blot using a 10% poly-acrylamide gel, loading 25 µg 
protein per lane. The samples were from animals in the control, 
indomethacin-treated (Indo), zinc-pretreatment plus indomethacin (Indo + 
Zn) and zinc (Zn) only groups (n=5 in each group). This shows a 
representative blot with pro-MMP-9 (92kD) bands. β-actin bands show 
equal protein loading in all lanes. 
 
 
 
Figure 8B: Relative concentrations of pro-MMP-2 in renal homogenates, 
24 hours after indomethacin administration, as assessed by Western blot 
using a 10% poly-acrylamide gel, loading 25 µg protein per lane. Data 
represents means of pro-MMP-2 protein levels (± SEM)), obtained by 
image analysis of Western blots with the concentration of the controls set 
at one.  
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3. Studies on MMP-2 
3.1. Effect of varying doses of indomethacin on MMP-2 activity in rat kidney, 24 
hours after the dose of the drug  
Preliminary zymograms did not show any conclusive changes in the trends of MMP-2 
activity (Figure 9A). The precision of densitometric measurements was reduced for 
MMP-2 as the intensity of the band was low. The bands for MMP-2 were not clearly 
visible in our preliminary western blots and are hence not reported. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9A: MMP-2 activity in renal homogenates in response to varying 
doses of indomethacin. Data are means of MMP-2 activity (±SEM), n=2, 
obtained by image analysis of zymograms, with the activity of the controls 
set at one.  
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3.2. Effect of zinc pretreatment on indomethacin-induced effects on MMP-2 in rat 
kidney, 24 hours after administration of indomethacin 
Analysis of data by ANOVA showed that there were overall significant differences 
between the groups. When applying the Bonferroni’s correction as a post-hoc test, it was 
found that pretreatment with zinc in animals given indomethacin tended to increase 
MMP-2 activity, but the effect did not reach statistical significance (p = 0.08) (Figure 
10A). Protein levels of MMP-2 were not affected by pre-treatment with zinc in any of the 
experimental groups (Figure 10B).  
 
 
 
Figure 10A: MMP-2 (65kD) activity in renal homogenates. The samples 
were from animals in the control, indomethacin-treated (Indo), zinc-
pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) only groups. 
Data are means of activity of MMP-2 (± SEM), obtained by image 
analysis of zymograms, with the activity of the controls set at one;  n=6. 
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Figure 10B: Relative concentrations of MMP-2 in renal homogenates, 24 
hours after indomethacin administration, as assessed by Western blot 
using a 10% poly-acrylamide gel, loading 25 µg protein per lane. Data 
represents means of MMP-2 protein levels (± SEM)), obtained by image 
analysis of Western blots with the concentration of the controls set at one.  
 
 
 
 
 
 
 
 
4. Studies on TIMP-2 
4.1. Effect of varying doses of indomethacin on levels of TIMP-2 in rat kidney, 24 
hours after the dose of the drug  
A preliminary study on the effects of varying doses of indomethacin on TIMP-2 
expression levels, as assessed by Western blot, showed that the protein levels tended to 
decrease with increasing doses of indomethacin (Figures 11A and 11B). 
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Figure 11A: Western blot showing effects of various doses of 
indomethacin on protein expression of TIMP-2 in renal homogenates, 24 
hours after the drug. This is a representative blot of using a 10% poly-
acrylamide gel, with 25 µg of protein loaded per lane. β-actin was used as 
a protein loading control. 
 
 
 
 
 
Figure 11B: Relative concentrations of TIMP-2 in renal homogenates, 24 
hours after indomethacin administration, as assessed by Western blot 
using a 10% poly-acrylamide gel, loading 25 µg protein per lane. Data 
represents means of TIMP-2 protein levels ± standard error of mean 
(SEM)), obtained by image analysis of Western blots with the 
concentration of the controls set at one.  n = 2 
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4.2. Effect of zinc pretreatment on indomethacin-induced effects on TIMP-2 in rat 
kidney, 24 hours after administration of indomethacin 
Pretreatment with zinc did not affect indomethacin-induced changes in TIMP-2 (Figure 
12A and 12B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12A: Relative concentrations of TIMP-2 in renal homogenates, 24 
hours after indomethacin (20mg/kg) administration, as assessed by Western 
blot using a 10% poly-acrylamide gel, loading 25 µg protein per lane. The 
samples were from animals in the control, indomethacin-treated (Indo), zinc-
pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) only groups (n=6 
in each group). This shows a representative blot with TIMP-2 bands. β-actin 
bands show equal protein loading in all lanes. 
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Figure 12B: Relative concentrations of TIMP-2 in renal homogenates, 24 
hours after indomethacin administration, as assessed by Western blot 
using a 10% poly-acrylamide gel, loading 25 µg protein per lane. Data 
represent means of MMP-2 protein levels (± SEM)), obtained by image 
analysis of Western blots with the concentration of the controls set at one. 
* indicates p<0.05 as compared to control group.   
 
 
5.Studies on TIMP-1 
5.1. Effect of indomethacin (20mg/kg) on TIMP-1 levels in rat kidney, 24 hours after 
the dose of the drug 
Indomethacin was found to significantly reduce TIMP-1 levels in the renal homogenate 
(Figure 13A).  
 
5.2. Effect of zinc pretreatment on indomethacin-induced effects on TIMP-1 in rat 
kidney, 24 hours after administration of indomethacin: 
Pretreatment with zinc showed a tendency to reverse the drug-induced decrease in TIMP-
1 levels but the effect did not attain statistical significance (Figure 13B). 
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Figure 13A: Relative concentrations of TIMP-1 in renal homogenates, 24 
hours after indomethacin (20mg/kg) administration, as assessed by 
Western blot using a 10% poly-acrylamide gel, loading 25 µg protein per 
lane. The samples were from animals in the control, indomethacin-treated 
(Indo), zinc-pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) 
only groups (n=4 in each group). This shows a representative blot with 
TIMP-1 bands. β-actin bands show equal protein loading in all lanes. 
 
 
 
 
Figure 13B: Relative concentrations of TIMP-1 in renal homogenates, 24 
hours after indomethacin administration, as assessed by Western blot 
using a 10% poly-acrylamide gel, loading 25 µg protein per lane. Data 
represent means of MMP-2 protein levels (± SEM), obtained by image 
analysis of Western blots with the concentration of the controls set at one. 
* indicates p<0.05 as compared to control group.   
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6. Studies on other gelatinases in the rat kidney 
Gelatin zymograms showed the activity of other gelatinolytic enzymes in the rat kidney 
homogenates. 
6.1. Effect of indomethacin on other gelatinases in the rat kidney 24 hours after the 
drug:  
Treatment with indomethacin 20mg/kg did not significantly alter the activity of the other 
gelatinases in the rat kidney (Figures 14 and 15). 
 
6.2. Effect of zinc pretreatment on indomethacin-induced effects on other 
gelatinases in the rat kidney, 24 hours after administration of indomethacin 
Zinc pretreatment, either alone or before the indomethacin, did not produce any changes 
in the activity of these gelatinases (Figures 14 and 15) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14A: Activity of other gelatinolytic enzymes 24 hours after the 
dose of indomethacin, as assessed by gelatin zymography on a 6% poly-
acrylamide gel, loading 5 µg renal homogenate protein per lane, obtained 
from control, indomethacin treated (Indo), zincs pretreated (Indo + Zn) 
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and zinc (Zn) only groups. This is a representative zymogram (n=5) (A) 
showing white bands of molecular weights ~170kD, ~130kD and ~100kD 
with gelatinase activity. HT-1080 cell line media served as a positive 
control for the pro-MMP-9, pro-MMP-2 and MMP-2 activity. 
 
Figure 14B: 170 KD gelatinase activity in renal homogenates. The 
samples were from animals in the control, indomethacin-treated (Indo), 
zinc-pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) only 
groups. Data are means of activity (± SEM), obtained by image analysis of 
zymograms, with the activity of the controls set at one; n=6. 
 
Figure 15A: 130 KD gelatinase activity in renal homogenates. The 
samples were from animals in the control, indomethacin-treated (Indo), 
zinc-pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) only 
groups. Data are means of activity (± SEM), obtained by image analysis of 
zymograms, with the activity of the controls set at one; n=6. 
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Figure 15B: 100 KD gelatinase activity in renal homogenates. The 
samples were from animals in the control, indomethacin-treated (Indo), 
zinc-pretreatment plus indomethacin (Indo + Zn) and zinc (Zn) only 
groups. Data are means of activity (± SEM), obtained by image analysis of 
zymograms, with the activity of the controls set at one; n=6. 
 
 
7. Studies on assessment of renal function in the experimental 
animals 
7.1. Effects of indomethacin and zinc pretreatment on serum creatinine and urea 
levels in rats 
7.1.1.  Effects of indomethacin on blood urea and serum creatinine levels 24 hours 
after the drug 
The levels of blood urea and serum creatinine were found to be significantly higher in the 
indomethacin-treated rats as compared with levels in control animals (Figures 16A and 
16B).  
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7.1.2. Effects of zinc pretreatment on indomethacin-induced changes in blood urea 
and serum creatinine levels 24 hours after the drug  
Pre-treatment with zinc did not significantly alter indomethacin-induced increases in 
blood urea and serum creatinine 24 hours after the drug (Figures 16A and 16B). 
 
Figure 16A: Effects of indomethacin (20mg/kg body weight) on blood 
urea levels in rats sacrificed 24hours after the dose of drug. Data are 
represented as means (± SEM); n=5 for control; n=3 for other groups.  
 * indicates p<0.05 as compared to control groups. 
 
 
Figure 16B: Effects of indomethacin (20mg/kg body weight) on serum 
creatinine levels in rats sacrificed 24hours after the dose of drug. Data are 
represented as means (±SEM); n=5 for control; n=3 for other groups.  
* indicates p<0.05 as compared to control groups.  
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. 
 
 
7.1.3. Study on creatinine levels over time in animals treated with indomethacin, 
with and without pretreatment with zinc 
Creatinine levels were increased to a significant extent in indomethacin-treated rats, from 
12 hours (after the dose of indomethacin) onwards and remained at this level up to 72 
hours, after which it began to fall, reaching close to baseline values by 120 hours. 
Animals pretreated with zinc showed similar trends but the levels began to fall earlier, i.e. 
soon after 24 hours. Treatment with zinc alone produced effects similar to Indo+ Zn on 
serum creatinine (Figure 17). 
Figure 17: A preliminary (n=1) 5-day time course study of serum 
creatinine levels in control, indomethacin treated (Indo), zinc 
pretreated (Indo+Zn) and zinc (Zn) only groups.  
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DISCUSSION 
 
 
This study attempted to determine whether matrix metalloproteinases-2 and -9 and their 
inhibitors, TIMP-1 and TIMP-2, are involved in the pathogenesis of indomethacin-
induced renal dysfunction. We have shown that indomethacin, at 20mg/kg, increases pro-
MMP-9 activity and decreases the levels of TIMP-1 and TIMP-2 in rat kidney. In 
addition, it is seen that these indomethacin-induced effects are not affected by prior 
administration of zinc. We also show that zinc does not affect indomethacin-induced 
changes in renal function, but it appears to tend to facilitate recovery from these changes.  
 
Oxidative stress has been proposed as a critical initiator of indomethacin-induced renal 
damage (Basivireddy et al., 2004). The sources of oxidants resulting in such stress may 
be both in the intracellular and extracellular compartments. Changes in the balance of 
activities of pro- and antioxidant enzymes, a fall in glutathione levels and increased 
production of ROS by mitochondrial uncoupling are the major intracellular sources that 
contribute to oxidative stress (Somasundaram et al., 1997, Nieto et al., 2002, Villegas et 
al., 2002). Neutrophil infiltration and activation and reactive drug metabolites are the 
major causes for such a stress in an extracellular environment (Basivireddy et al., 2004, 
Lee et al., 1992, Asako et al., 1992). The reported effects of indomethacin-induced 
oxidative stress on the ultra-structure of renal tubular cells include mitochondrial 
swelling, intracytoplasmic vacuolation and inclusion bodies, all of which are pathological 
phenotypes resembling acute tubular injury (Basivireddy et al., 2004). Oxidative stress, 
also induced in other forms of acute renal injury, is a known modulator of extra-cellular 
matrix remodeling in the kidney (Sachse and Wolf, 2007). Thus, the drug-induced effects 
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seen in the kidney suggest the possibility that extra-cellular matrix remodelling may be 
an important factor in both the pathogenesis and recovery of indomethacin-induced renal 
damage. This prompted us to look at the effect of indomethacin on matrix 
metalloproteinases and their inhibitors TIMPs.  
 
 The preliminary dose response studies done showed an initial rise in the activity of pro-
MMP-9, which was followed by a fall in activity. The peak activity was seen at a dose of 
20mg/kg (Figure 1). Previous studies done in our laboratory have shown significant 
oxidative stress occurring in the kidney at this dose of indomethacin (Basivireddy et al., 
2004). Analysis for changes in the protein content of pro-MMP-9, by Western blot, did 
not show any significant changes with increasing doses of indomethacin (Figure 2). 
These findings suggest an enhancement of pro-MMP-9 enzyme activity in the rat kidney 
without changes in the levels protein. This is in response to a 20mg/kg dose of 
indomethacin 24 hours after the drug. 
 
Moderate elevations in the levels of reactive oxygen species have been reported to 
increase the activity of pro-MMP-9 (Rajagopalan et al., 1996). The process of S-
glutathiolation of pro-MMP-9 has been described as a regulator of this increase in 
activity (Okamoto et al., 2001). Indomethacin is known to induce the generation of ROS 
and increase tissue levels of oxidized glutathione (Basivireddy et al., 2004, Nieto et al., 
2002). Exposure of thiol-containing proteins to such environments induces S-
glutathiolation (Chen et al., 2007, Shackelford et al., 2005). S-glutathiolation, in addition 
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to being a rapid regulator of enzyme activity, is a cellular defense mechanism, which 
maintains the stability of thiol groups during oxidant exposure (Shackelford et al., 2005). 
Based on these reports, we hypothesize that S-glutathiolation of pro-MMP-9 may be the 
mechanism involved in the increase in MMP-9 activity observed in our study.  
 
 High levels of oxidative stress have also been shown to oxidize vital amino-acid residues 
and inhibit pro-MMP-9 enzyme activity (Rajagopalan et al., 1996). It is possible that 
doses of indomethacin higher than 20mg/kg may induce proportionately greater changes 
in the redox environment. This implies that the fall in pro-MMP-9 activity observed at 
higher doses of indomethacin in this study may be a result of higher levels of oxidative 
stress. However, this is speculative and needs to be confirmed by estimating parameters 
of oxidative stress with increasing doses of indomethacin. 
 
No significant changes were observed in pro-MMP-2 or cleaved MMP-2 activities or 
levels of their proteins in response to a 20mg/kg dose of indomethacin, 24 hours after the 
drug the drug (Figure 6 and Figure 9). Pro-MMP-2 activity was found to peak at a dose of 
10mg/kg (Figure 5). Pro-MMP-2 activity at an indomethacin dose of 20mg/kg decreases 
to levels similar to that in the control group and hence does not appear to be significant at 
24 hours. These are, however, preliminary studies. Further studies with a lower dose of 
indomethacin (10mg/kg) are required to determine whether significant effects of the drug 
on pro-MMP-2 and oxidative stress do occur at this dose. It is possible that oxidative 
stress may be involved in modulating the activity of pro-MMP-2 also. This would need to 
be confirmed with further studies.  
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Preliminary studies showed a decrease in the expression levels of TIMP-2 with increasing 
doses of indomethacin. The decreases were marked at all the doses of indomethacin used 
(Figure 11). Studies assessing TIMP-1 levels showed similar result with 20mg/kg 
indomethacin at 24 hours (Figure 13). These studies, thus, show that indomethacin, at a 
dose of 20mg/kg, reduced both TIMP-2 and TIMP-1 levels in the kidney. 
 
The studies that followed were done to assess the effects of 20mg/kg dose indomethacin 
at 24 hours, at which time point, significant levels of oxidative stress were previously 
observed in the kidney (Basivireddy et al., 2004). The results confirmed the findings in 
the dose-response study and showed a significant decrease in TIMP-2 activity in the 
kidney on administering indomethacin.  
 
Levels of TIMP-2 fell significantly with indomethacin, starting with the lowest dose of 
10mg/kg (Figure 11B). This did not correlate with our observations on MMP-9 activity, 
which have shown marked increases in activity at doses of 10, 20 and 40 mg/kg (Figure 
1B). It thus appears that TIMP-2 does not appear to be the major regulator of MMP-9 
activity. Other known regulators of activity of this enzyme activity include tissue factor 
pathway inhibitor-2 (TFPI-2), thrombospondin 1 and 2, alpha-2 macroglobulin and reversal-
inducing cysteine rich protein with Kazal motifs (RECK) (Visse and Nagase, 2003). These 
regulators as well in response to oxidative stress may influence the activity of pro-MMP-9. Thus 
is necessary to establish the role of these other regulators in response to oxidative stress in the 
kidney in further studies. 
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TIMP-1 has been shown to be inactivated by reactive oxygen species like ONOO- at low 
concentrations (<100µM) and in a dose-dependent manner (Frears et al., 1996). Higher 
concentrations (500µM-5mM) of peroxynitrite cause protein fragmentation (Frears et al., 
1996). Studies also suggest a role of ONOO- in inactivating and decreasing TIMP-2 
levels (Chakraborti et al., 2004). Peroxynitrate generation in response to indomethacin 
toxicity has been reported in the intestine (Konaka et al., 1999) and kidney (De Angelis et 
al., 2004). On the basis of these reports, we hypothesize that indomethacin-induced 
increases in peroxynitrates may be involved in causing the changes we have observed in 
the levels of TIMPs in the kidney. This would need to be confirmed by measuring 
peroxynitrates in the kidneys of the experimental animals.  
 
These findings give insights into extracellular matrix turnover in acute indomethacin-
induced renal toxicity. The results suggest a renal environment with high levels of pro-
matrix-metalloproteinase–9 activity and low levels of the inhibitory proteins, TIMP-2 and 
TIMP–1. Such a state at this time point after the drug would suggest that matrix 
breakdown predominates over biosynthesis. Degradation of the tight junction protein, 
zonula occludens-1 between the tubular cells and occludin in endothelial cells in the 
glomerulus, is linked to the increased activity of MMP-9 in the kidney. This has been 
reported to result in tubular dysfunction and increased vascular permeability (Catania et 
al., 2007). 
 
Zinc is a well-known antioxidant. Its efficacy in conferring protection to the gastric 
mucosa by virtue of its antioxidant actions has been previously reported (Joseph et al., 
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1999). Studies done in our laboratory on the effects of zinc on indomethacin-induced 
oxidative damage in both the kidney (unpublished data) and intestine (Basivireddy et al, 
2002 and 2003) have also demonstrated its protective effects.  In our current study, it was 
found that zinc did not alter indomethacin-induced changes in matrix-metalloproteinases 
or their inhibitors. This observation was contrary to expectations.  It, thus, appears that 
zinc does not produce its protective effect by affecting the activities of MMP and TIMP 
in the kidney. Its cytoprotective effects are thus likely to be mediated through other 
mechanisms. 
 
 It is important to note, that zinc is not an antioxidant by itself (Powell, 2000). The 
protection offered by zinc is attributed to both acute and chronic downstream effects. 
Acute effects of zinc include stabilization of sulfhydryl groups and displacement of 
redox-active transition metals from macromolecules. Chronic effects of the metal are 
mediated by the induction of metallothioneins, which act as ultimate antioxidants 
(Powell, 2000). It is interesting to note that both these mechanisms are most effective 
intracellularly. This is further supported by the fact that the concentrations of zinc are 
higher in the intracellular compartment than in the extracellular environment (Onosaka 
and Cherian, 1982). Plasma levels of zinc are very low and are, in fact, tightly regulated 
(Wise, 1995). Post-transcriptional modifications play a major role in the regulation of 
MMPs and their inhibitors. These changes most often occur at an extracellular site and 
hence may not be influenced by intracellular antioxidants. Thus, it may be that zinc is 
probably more active as an intracellular antioxidant and has very little role in mediating 
changes occurring in the extracellular environment. This may account for our findings 
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that zinc did not affect indomethacin-induced effects on MMP and TIMP in our studies. 
It would be interesting to assess the role of other antioxidants, such as TEMPOL that are 
effective in the extracellular environment, in further studies.  
 
In an attempt to further study the protective effect of zinc, we looked at markers of renal 
function, viz., serum creatinine and blood urea 24 hours after the dose of indomethacin 
(Figure: 16). We found that indomethacin at a dose of 20mg/kg significantly increased 
levels of both blood urea and serum creatinine. Pre-treatment with zinc did not 
significantly affect these drug-induced changes. We concluded that from these data that 
zinc does not directly affect the action of indomethacin on renal function. The rise in urea 
and creatinine are likely to be due to a drug-induced decrease in the GFR, an effect that 
has been reported in response to administration of NSAIDs (Morgan and Anderson, 2003). 
Since zinc confers antioxidant protection primarily within cells, we hypothesized that the 
zinc may hasten recovery of indomethacin-induced impairment of renal function. We did 
a preliminary time course study to ascertain if our hypothesis was correct (Figure: 17). 
The results of this study appear to indicate that it is so. However, this would need 
confirmation with more animals being studied.  
 
Another intriguing finding we have observed is that that animals given zinc alone also 
demonstrated increases in serum creatinine. The cause for this effect is yet unknown and 
needs to be confirmed with more studies. If found to be consistent, it is a finding that will 
be of interest and will merit future studies. 
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• STUDY LIMITATIONS 
The limitations of this study is as follows: 
1. The sample size in our preliminary studies is limited to two batches. In order to 
comment on the significance of the obtained trends we must have a minimum 
sample size of six batches for analysis.  
2. We base many of our findings on the assumption that increasing doses of 
indomethacin cause a propotional increase in renal oxidative stress. A dose-
response study on levels of oxidative stress in the kidney in response to increasing 
doses of indomethacin is a must to acertian this assumption. 
The above-mentioned limitations are solely due to constraints of time. We are 
attempting to complete our study and plug these deficiencies in course of time. 
 
CONCLUSION 
Indomethacin, a prototypical NSAID increases pro-MMP-9 activity, decreases the 
expression levels of TIMP-1 and TIMP-2 and induces renal dysfunction at doses that 
induce significant oxidative stress in the kidney. The intracellular antioxidant zinc does 
not reverse these changes.  
In conclusion, this study has enabled us to gain a better understanding of the role of the 
proteinase-antiproteinase balance in indomethacin-induced renal injury. It further extends 
our knowledge on the role of zinc as an agent to reduce NSAID-induced renal damage. 
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FUTURE PLANS 
 
The future plans for this study is as follows: 
1. We plan to establish the changes in MMP-binding of TIMP-1 and TIMP-2 in 
response to indomethacin induced oxidative stress by reverse zymography. 
2. The role of zinc in hastening recovery in NSAID mediated renal damage must be 
evaluated. 
3. We would like to evaluate the effects of extracellular antioxidants on the changes 
in MMP activity. 
4. We intend to study role of nitrosative stress in indomethacin induced renal 
toxicity.  
5. We intend to study histopathological changes associated with indomethacin 
toxicity and correlate this with changes in MMP activity in the kidney by in-situ-
zymography. 
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Appendix I 
 
1. Raw and normalized data from preliminary study: 
 
 
Zymogram: Dose response indomethacin vs. pro-MMP-9 (preliminary data); raw 
data 
 0 10mg/kg 20mg/kg 40mg/kg 60mg/kg 
 
Batch 1 549 3231 4137 2373 1775 
 
Batch 2 549 2544 4394 1571 53 
All values are as obtained on densitometric quantification of zymograms and are 
expressed as arbitary units 
 
 
 
Zymogram: Dose response indomethacin vs. pro-MMP-9 (preliminary data); 
normalized data (as a ratio of the control value) shown in Figure 1B 
 0 10mg/kg 20mg/kg 40mg/kg 60mg/kg 
 
Batch 1 1 5.885246 7.535519 4.322404 3.233151 
 
Batch 2 1 4.63388 8.166742 2.861566 0.096539 
All values are as obtained on densitometric quantification of zymograms and are 
expressed as ratios 
 
 
 
 
Zymogram: Dose response indomethacin vs. pro-MMP-2 (preliminary data); raw 
data 
 0 10mg/kg 20mg/kg 40mg/kg 60mg/kg 
 
Batch 1 12971 19535 14221 12233 9876 
 
Batch 2 28538
1
 20049 264591 9824 9076 
All values are as obtained on densitometric quantification of zymograms and are 
expressed as arbitary units 
1 results from a different gel compared to each other for normalization 
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Zymogram: Dose response indomethacin vs. pro-MMP-2 (preliminary data); 
normalized data (as a ratio of the control value) shown in Figure 5B 
 0 10mg/kg 20mg/kg 40mg/kg 60mg/kg 
 
Batch 1 1 1.506052 1.096369 0.943104 0.761391 
 
Batch 2 1 1.545679 0.92715 0.757382 0.699715 
All values are as obtained on densitometric quantification of zymograms and are 
expressed as ratios 
 
 
 
 
 
Zymogram: Dose response indomethacin vs. MMP-2 activity (preliminary data); 
raw data 
 0 10mg/kg 20mg/kg 40mg/kg 60mg/kg 
 
Batch 1 2931 8182 4434 8110 1989 
 
Batch 2 5535 14232 4431 4909 1187 
All values are as obtained on densitometric quantification of zymograms and are 
expressed as arbitary units 
 
 
 
 
 
 
Zymogram: Dose response indomethacin vs. MMP-2 activity (preliminary data); 
normalized data (as a ratio of the control value) shown in Figure 9A 
 0 10mg/kg 20mg/kg 40mg/kg 60mg/kg 
 
Batch 1 1 2.791539 1.512794 2.766974 0.678608 
 
Batch 2 1 4.855681 0.80054 1.674855 0.404981 
All values are as obtained on densitometric quantification of zymograms and are 
expressed as ratios 
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Western blot: Dose response indomethacin vs. pro-MMP-9 levels (preliminary 
data); normalized data as shown in Figure 2B 
 0 10mg/kg 20mg/kg 40mg/kg 60mg/kg 
 
Batch 1 1 1.217296 1.328207 0.764003 0.640962 
 
Batch 2 1 1.414008 1.29635 1.067972 2.521795 
All values are as obtained on densitometric quantification of western blots and are 
expressed as ratios 
 
 
 
 
 
Western blot: Dose response indomethacin vs. pro-MMP-2 levels (preliminary 
data); normalized data as shown in figure 6B 
 0 10mg/kg 20mg/kg 40mg/kg 60mg/kg 
 
Batch 1 1 1.002556 0.957317 0.81371 0.934626 
 
Batch 2 1 1.02387 1.03092 1.122563 1.076759 
All values are as obtained on densitometric quantification of western blots and are 
expressed as ratios 
 
 
 
 
 
 
Western blot: Dose response indomethacin vs. TIMP-2 levels (preliminary data); 
normalized data (as a ratio of the control value) shown in Figure 11B 
 0 10mg/kg 20mg/kg 40mg/kg 60mg/kg 
 
Batch 1 1 0.311944 0.146998 0.066769 0.03337 
 
Batch 2 1 0.254419   0.18353  0.151006 0.179641 
All values are as obtained on densitometric quantification of western blots and are 
expressed as ratios 
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2. Zymography and western blot data with 20mg/kg indomethacin dosing 
 
• Zymogram: Pro-MMP-9 activity; raw data 
  Control Indo Indo+Zn Zn 
• Batch 1 •  20884 35190 41318 10592 
Batch 2  13077 24310 35954 11849 
Batch 3  14668 26006 12926 10003 
Batch 4  7125 15903 15970 6553 
Batch 5  10363 13812 15287 10826 
Batch 6  4213 6928 9490 2832 
All values are as obtained on densitometric quantification of zymograms and are 
expressed as arbitary units 
 
 
 
 
 
 
 
 
• Zymogram: Pro-MMP-9 activity; normalized data (as a ratio of the control value) 
shown in Figure 3B 
  Control Indo Indo+Zn Zn 
• Batch 1 •  1 1.685022 1.978452 0.507183 
Batch 2  1 1.858989 2.749407 0.906095 
Batch 3  1 1.772975 0.881238 0.681961 
Batch 4  1 2.232 2.241404 0.919719 
Batch 5  1 1.332819 1.475152 1.044678 
Batch 6  1 1.644434 2.252552 0.672205 
All values are as obtained on densitometric quantification of zymograms and are expressed 
as ratios 
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• Zymogram: Pro-MMP-2 activity; raw data 
 Control Indo Indo+Zn Zn 
• Batch 1 54105 36436 84457 65808 
Batch 2 30433 73047 40598 46242 
Batch 3 28538 26459 19815 29043 
Batch 4 24537 46600 17719 26547 
Batch 5 20403 12862 15939 32173 
Batch 6 24860 22484 18026 18562 
All values are as obtained on densitometric quantification of zymograms 
 and are expressed as arbitary units 
 
 
 
 
 
• Zymogram: Pro-MMP-2 activity; normalized data (as a ratio of the control value) 
shown in Figure 7B 
 Control Indo Indo+Zn Zn 
• Batch 1 1 0.673431 1.560983 1.216302 
Batch 2 1 2.400256 1.334012 1.519469 
Batch 3 1 0.92715 0.694337 1.017696 
Batch 4 1 1.899173 0.722134 1.081917 
Batch 5 1 0.630397 0.781209 1.576876 
Batch 6 1 0.904425 0.725101 0.746661 
All values are as obtained on densitometric quantification of zymograms 
 and are expressed as ratios 
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• Zymogram: MMP-2 (active) activity; raw data 
 Control Indo Indo+Zn Zn 
• Batch 1 13113 3889 19309 21735 
Batch 2 7220 2218 13510 12797 
Batch 3 5487 3158 13233 11753 
Batch 4 2137 5441 7938 7945 
Batch 5 5535 4431 7104 5031 
Batch 6 6829 4581 12929 5830 
All values are as obtained on densitometric quantification of zymograms 
 and are expressed as arbitary units 
 
 
 
 
• Zymogram: MMP-2 (active) activity; normalized data (as a ratio of the control value) 
shown in Figure 10A 
 Control Indo Indo+Zn Zn 
• Batch 1 1 0.296576 1.472508 1.657515 
Batch 2 1 0.307202 1.871191 1.772438 
Batch 3 1 0.575542 2.4117 2.141972 
Batch 4 1 2.546093 3.714553 3.717829 
Batch 5 1 0.800542 1.283469 0.908943 
Batch 6 1 0.670816 1.893249 0.853712 
All values are as obtained on densitometric quantification of zymograms 
 and are expressed as ratios 
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• Western blot: Pro-MMP-9/β-actin levels; normalized data (as a ratio of the control value) 
shown in Figure 4B 
 Control Indo Indo+Zn Zn 
• Batch 1 1 1.116147741 1.244672557 1.188461538 
Batch 2 1 0.922498154 0.952920412 0.968459945 
Batch 3 1 1.071343639 1.397877984 0.818477554 
Batch 4 1 0.673733172 0.861665014 0.820560229 
Batch 5 1 1.296352523 0.455407645 0.527039106 
All values are as obtained on normalization of densitometric quantification of western blot 
 and are expressed as ratios 
 
 
 
 
 
• Western blot: Pro-MMP-2/β-actin levels; normalized data (as a ratio of the control 
value) shown in Figure 7B 
 Control Indo Indo+Zn Zn 
• Batch 1 1 0.879703489 1.215255865 1.07357022 
Batch 2 1 1.09375 1.049744077 1.07664679 
Batch 3 1 1.030915577 1.194960212 0.685751464 
Batch 4 1 0.821023288 1.601812026 1.253395222 
Batch 5 1 1.037340521 0.776130764 2.426864785 
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All values are as obtained on normalization of densitometric quantification of western blot 
 and are expressed as ratios 
 
 
 
 
 
• Western blot: MMP-2/β-actin levels; normalized data (as a ratio of the control value) 
shown in Figure 10B 
 Control Indo Indo+Zn Zn 
• Batch 1 1 0.467120181 0.518717475 0.511801242 
Batch 2 1 0.379464286 0.944021676 1.549586777 
Batch 3 1 0.488505747 0.544871795 0.962264151 
Batch 4 1 1.826659972 1.577759456 1.689008043 
Batch 5 1 0.691460737 0.409087469 1.040571266 
All values are as obtained on normalization of densitometric quantification of western blot 
 and are expressed as ratios 
 
 
 
 
 
 
 
• Western blot: TIMP-2/β-actin levels; normalized data (as a ratio of the control value) 
shown in Figure 12B 
 Control Indo Indo+Zn Zn 
• Batch 1 1 0.797994 0.798992 1.014535 
Batch 2 1 0.262911 0.434491 0.29353 
Batch 3 1 0.937899 0.974542 0.997927 
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Batch 4 1 0.183528 0.057588 0.285932 
Batch 5 1 0.388891 0.282928 0.679895 
Batch 6 1 1.003787 0.965801 0.857938 
All values are as obtained on normalization of densitometric quantification of western blot 
 and are expressed as ratios 
 
 
 
 
 
 
• Western blot: TIMP-1/β-actin levels; normalized data (as a ratio of the control value) 
shown in Figure 13B 
 Control Indo Indo+Zn Zn 
• Batch 1 1 0.572944 1.18326 1.019159 
Batch 2 1 0.302662 0.443319 1.112235 
Batch 3 1 0.508587 0.507956 0.941008 
Batch 4 1 0.506012 1.14883 1.167765 
All values are as obtained on normalization of densitometric quantification of western blot 
 and are expressed as ratios 
 
 
 
 
 
3. Data for estimation of blood urea and serum creatinine: 
 
 
 
• Blood urea levels in rats (mg%) 
 Control Indo Indo+Zn A Indo+Zn B 
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• Batch 1 6.43 12.5 15 13.21 
Batch 2 6.07 16.07 18.57 6.79 
Batch 3 2.86 7.14 10.71  
Batch 4 4.64 7.5   
Batch 5 7.5    
 
 
 
 
• Serum creatinine levels in rats (mg%) 
 Control Indo Indo+Zn A Indo+Zn B 
• Batch 1 1.1 1.7 2.3 1.7 
Batch 2 0.81 1.7 2.3 2.2 
Batch 3 1.2 2.25 2.1 1.1 
Batch 4 0.72 1.97 2.1  
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Appendix II 
 
Standard curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard graph for molecular weights on 10% PAGE
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Reaction rate curve for urea
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